question,question_raw,contexts,contexts_raw,ground_truth,evolution_type,metadata,episode_done
多器官功能障碍综合征如何影响脓毒症患者的治疗方案？,多器官功能障碍综合征如何影响脓毒症患者的治疗方案？,[''],"['�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�']",nan,no_reference,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
多学科团队在中国的ECMO治疗中扮演着怎样的角色？,多学科团队在中国的ECMO治疗中扮演着怎样的角色？,[''],"['新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']",多学科团队在中国的ECMO治疗中扮演着关键角色。ECMO技术的复杂性和高风险要求一个多学科团队共同合作，而不是由单一科室完成。然而，由于多学科背景的存在，实际开展中存在学科归属不明确的情况，如心外科、重症医学科和呼吸科都参与ECMO的开展。不同医院开展ECMO的科室也有差异，这导致了学科管理的分散，限制了统一组织多学科合作以及相关指南与研究的推进。因此，建设ECMO中心除了要考虑人员和设备配置外，还应考虑到每年中心可能开展的病例数。ELSO建议ECMO中心的年开展例数应≥6例。,no_reference,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
"Given the context, a question about tidal volume reduction could be: 

对于ARDS/ALI患者，为什么需要降低潮气量？","Given the context, a question about tidal volume reduction could be: 

对于ARDS/ALI患者，为什么需要降低潮气量？",[''],"[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']",对于ARDS/ALI患者，降低潮气量的目的是为了降低气道压力和潮气量，从而减少肺损伤和改善预后。多个研究表明，限制潮气量可以降低死亡率，并且允许高碳酸血症在一定范围内可以减少气道压力和潮气量，但需要注意避免已有代谢性酸中毒或颅内压增高的患者。,no_reference,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
脓毒症导致的ARDS治疗方案中，哪些措施被推荐采用？,脓毒症导致的ARDS治疗方案中，哪些措施被推荐采用？,[''],"['通气持续时间无影响，但 HFOV 组患者气压伤发生率增加。 俯 卧位通气可降低胸膜腔压力梯度，提高胸壁顺应性， 促进分泌物的清除， 从而改善 ARDS 患者的通气。对于 PaO2/FiO2＜150mmHg 的 ARDS 患者， 与仰卧位相比，在插管开始后的 前 36h内 ，每天进行 16h以上俯卧位通气可提高生存率。 包括该研究在内的 Meta 分析显 示，俯卧位治疗可降低患者病死率， 改善氧合作用。大多数患者采用俯卧位可改善氧合并可 能改善肺顺应性。\n推荐意见 29：建议使用神经肌肉阻滞剂 (NMBAs)的时间≤48h (弱推荐， 中等证据 质量)。\nNMBA 在 ICU 中最普遍的适应证是促进机械通气。研究表明， 与安慰剂相比，Pa O2/Fi O2＜150mmHg 的早期 ARDS 患者连续输注顺式阿曲库铵与生存率的改善和器官功能正常时 间的延长相关， 且未增加 ICU 获得性肌无力的风险。 合并分析3项关于 NMBA 在 ARDS 中 的作用的试验， 结果显示，短疗程 (≤48h) 连续输注 NMBA 治疗患者的死亡风险及气压伤 风险均降低。 一项关于严重脓毒症患者的RCT 显示，在深度神经肌肉阻滞期间， 氧气输送、 氧气消耗及胃黏膜 pH 值无显著改善。\n推荐意见 30：对于脓毒症导致的 ARDS，如无组织低灌注证据', '，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�']",推荐意见 29：建议使用神经肌肉阻滞剂 (NMBAs)的时间≤48h (弱推荐， 中等证据 质量)。推荐意见 30：对于脓毒症导致的 ARDS，如无组织低灌注证据，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。,no_reference,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
How should the fluid resuscitation for patients with septic shock be initiated?,How should the fluid resuscitation for patients with septic shock be initiated?,[''],"['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","Fluid resuscitation for patients with septic shock should be initiated early, with a recommendation to administer at least 30ml/kg of crystalloid solution within 3 hours of diagnosing septic shock. This initial resuscitation should be followed by an assessment of hemodynamic status to guide further fluid use.",no_reference,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
如何评估机械通气患者是否满足脱机机械通气的标准，并在实施过程中采用哪些方法？,如何评估机械通气患者是否满足脱机机械通气的标准，并在实施过程中采用哪些方法？,[''],"[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']",机械通气患者是否满足脱机机械通气的标准可通过进行自主呼吸试验来评估。在实施过程中，患者需要满足以下标准：a)具有清醒能力；b)血液动力学稳定（无血管收缩剂）；c)呼吸频率＜30次/分；d)动脉氧分压＞50-60mmHg；e)动脉二氧化碳分压＜50mmHg或pH＞7.25；f)无意识障碍；g)无新的或进行性呼吸困难；h)呼吸肌力量强、有规律、无疲劳；i)氧饱和度＞90%（FiO₂＜40%时）。,no_reference,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
晶体溶液在脓毒性休克患者的液体复苏中扮演着什么样的角色？,晶体溶液在脓毒性休克患者的液体复苏中扮演着什么样的角色？,['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],晶体溶液在脓毒性休克患者的液体复苏中起着重要作用，推荐在拟诊为脓毒性休克起 3 小时内输注至少 30ml/kg 的晶体溶液进行初始复苏。,simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
在哪些情况下强烈推荐不使用B2-激动剂，即使出现支气管痉挛？,在哪些情况下强烈推荐不使用B2-激动剂，即使出现支气管痉挛？,"['                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ', '                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ', '                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ', '                                            | Schwache EmpfehlungEvidenz niedric                                              |\n| 14 | nan   | nan                                                           | nan                                                                                                                                                                          | Starke Empfehlung                                                               |\n| 15 | nan   | nan                                                           | nan                                                                                                                                                                          | Evidenz hochSchwache Empfehlung                                                 |\n| 16 | nan   | nan                                                           | Dobutamin bei Hypoperfusion trotz ausreichender Volumenbelastung und Vasopressorenthera-                                                                                     | Evidenz niedrio                                                                 |\n| 17 | H     | Kortikosteroide                 ', '                                                                                                                                                    | Starke EmpfehlungEvidenz hoch                       |\n| 14 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Schwache Empfehlunc                                 |\n| 15 | N      | nan                         | Oberkörperhochlagerung 30-45° beim beatmeten Patienter                                                                                                                                                                                                                                       | Starke EmpfehluncEvidenz niedrig                    |\n| 16 | N      | nan                         | Spontanatmungsversuche                                                                                           ']","['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ']",在哪些情况下强烈推荐不使用B2-激动剂，即使出现支气管痉挛的情况下，强烈推荐不使用B2-激动剂，除非出现支气管痉挛。,simple,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
脓毒性休克多药联合治疗的早期降阶梯与更好的临床预后相关吗？,脓毒性休克多药联合治疗的早期降阶梯与更好的临床预后相关吗？,"['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�', '体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�', '�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�']",['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�'],1,simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
balancierte Lösungen 在对于败血症性休克的液体管理中起到了什么作用？,balancierte Lösungen 在对于败血症性休克的液体管理中起到了什么作用？,"['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ']","['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ']",balancierte Lösungen在对于败血症性休克的液体管理中被推荐使用，但是只有低证据支持这一推荐。,simple,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
What is the role of positive end-expiratory pressure (PEEP) in respiratory physiology or mechanical ventilation?,What is the role of positive end-expiratory pressure (PEEP) in respiratory physiology or mechanical ventilation?,"[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in', ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in', ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","The role of positive end-expiratory pressure (PEEP) in respiratory physiology or mechanical ventilation is to prevent lung collapse at end-expiration. Setting a minimum positive end-expiratory pressure helps keep lung units open, which enhances gas exchange. This increase in Pao2₂ when positive end-expiratory pressure is applied through either an endotracheal tube or a face mask contributes to improved oxygenation.",simple,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
镇静剂使用在 ICU 脓毒症患者中的作用是什么？,镇静剂使用在 ICU 脓毒症患者中的作用是什么？,['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。,simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
抗菌药物治疗的启动是否推荐常规进行微生物培养？,抗菌药物治疗的启动是否推荐常规进行微生物培养？,['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。,simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
How do clinical studies assess the lactate levels and treatment outcomes in patients with septic shock?,How do clinical studies assess the lactate levels and treatment outcomes in patients with septic shock?,"['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '��入 12 个 RCTs 共计 9044 例患者的 Meta 分析显示参附注射液可显著降 低患者 LAC 水平。我国一项 RCT 研究显示监测血乳酸浓度能够提高复苏效果， 降低脓毒性 休克患者的病死率。以 6h 内血乳酸＜2mmol/L 作为目标指导复苏可明显改善预后。\n推荐意见 5：初始液体复苏及随后的容量替代治疗中，推荐使用晶体液(强推荐，中等 证据质量) 。与晶体液相比，应用胶体液无任何显著获益，且可能导致肾损伤以及凝血机制 异常等不良事件，同时胶体液价格较高， 因此强力推荐脓毒症和脓毒性休克患者的液体复苏 使用晶体液。有研究表明平衡晶体液和生理盐水进行复苏， 晶体液能降低 30d主要肾脏不 良事件发生率；高肌酐和高氯人群使用平衡晶体液避免主要肾脏不良事件获益最大。有研究 表明与限氯策略相比，含氯策略治疗的患者急性肾损伤和肾脏替代治疗(RRT) 的风险增高， 故无论使用哪种液体溶液， 均建议监测血清氯化物水平以避免高氯血症。\n推荐意见 6：不推荐使用羟乙基淀粉进行容量替代治疗 (强推荐，高证据质量)。\n目前已有多项研究对羟乙基淀粉 (HES) 在脓毒症患者中的安全性问题', 'RT 需求、 尿量、生存期、住院时间、 心律失常发生率等疗效指标均无显著改善。 我国相关研究表明， LDD 不能降低脓毒症急性肾衰竭患者 RRT 需求及病死率。\n推荐意见 21 ：经过充分的液体复苏以及使用血管活性药物后，如果仍持续低灌注，建 议使用多巴酚丁胺(弱推荐，低证据质量)。\n多巴酚丁胺作为一线正性肌力药，为 EGDT 临床试验标准治疗的一部份，在其使用中 未发现对病死率的不良影响。 两项 ICU 脓毒症患者的大型前瞻性临床试验显示，使用多巴 酚丁胺将患者心输出量提高至高于正常水平不会改善临床结局。然而， 一些患者可能通过正 性肌力药物改善组织灌注，增加氧气输送。我国一项评价多巴酚丁胺联用去甲肾上腺素治疗 脓毒性休克伴顽强性低血压的研究表明，多巴酚丁胺可有效升高血压， 改善循环与灌注，提 高救治成功率。\n推荐意见 22：建议所有需要血管活性药物的患者置入动脉导管进行连续性血压测定(弱 推荐， 极低证据质量)。\n在休克状态， 使用动脉导管监测血压比袖带血压计测量更准确，可进行连续监测且允许\n如有侵权请联系网站删除\n每搏分析，有助于医务人员更准确']",['映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�'],"Clinical studies assess lactate levels and treatment outcomes in patients with septic shock by closely monitoring early arterial blood lactate (LAC) levels, which are indicative of poor prognosis. Additionally, the 34-hour LAC levels and lactate clearance rate (LCR) effectively evaluate clinical treatment effectiveness and prognosis. Evaluation of lactate-guided resuscitation in 6477 patients with septic shock showed a significant decrease in mortality compared to those without lactate monitoring. Meta-analysis results indicate that early lactate clearance strategy reduces mortality compared to conventional care or ScvO2 monitoring. In an RCT evaluating the treatment of septic shock with compound danshen dripping pills, patients with LAC > 4.5mmol/L who received the treatment showed significantly improved 7-day survival rates compared to the control group.",simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
这本书的内容是什么？,这本书的内容是什么？,"['lichen Arbeit helfen, die für sich genommen jedoch nicht die grolse Aufmerksamkeit genie(βsen, können in ihre Addition einen signifikanten Einfluss auf da: Gelingen haben. Dieses Buch ist einzigartic in der einfachen, ehrlichen und praktischer Herangehensweise an das Thema,Thorax drainagen"" Das Buch stellt das Thema umfassend dar Es umfasst die Themenfelder Anatomie, Phy siologie, Indikationen, Art der Drainagen, Le gen einer Drainage, Komplikationen, Pflege Management des Pleuraspaltes, Schmerz therapie, Physiotherapie und Entfernen der Drainage. Ich habe viel gelernt, und ich wette dass jeder Thoraxchirurg, egal wie ertahrer er sein mag, in diesem Buch viele Dinge fn den wird, die interessant, uberraschend ung hilfreich sind und die ihm helten, seine Arbei für und mit den Patienten zu verbessern Einzigartig ist das Buch auch darin, sich durchgängig auf das zu beziehen, was wi aufarund wissenschaftlicher Arbeit wissen Ganz besonders im Umgang mit Thoraxdral nagen ist die Vorgehensweise der Klinike\n\nditionen, die vorhandene wissenschaftliche Evidenz tritt zumeist in der Hintergarunc Dieser Bereich illustriert sehr qut die Beob achtung von Stuart Chase, die er bereits 1888 gemacht hat: ,Für die, die glauben, brauch es keinen Beweis, für die, die nicht qlauben ist kein Beweis möglich"". Trotz der doama tischen Glaubensarundsätze und Lager di existieren, gibt es eine groBe Zahl seriöser Daten. Einige der wissenschaftlichen The men sind sicherlich noch nicht umfassend aufaearbeitet. aber Thomas Kiefer hat die existierenden wissenschaftlichen Frkennt nisse gründlich aufgearbeitet. Er hat diese Erkenntnisse an ieder Stelle in einer qut les baren, einfachen Art und Weise eingebracht immer offen und ehrlich betonend., was wi wissen und was wir nicht wissen. Dies führ dazu, dass er einige der häufig zitierten Dod men entlarvt-er tut dies in einer einfacher an Fakten orientieren und sachlichen Ar und Weise. Dieser autrichtige und sachliche Stil der Diskussion und das sich daraus er gebende Management, basierend auf der vorliegenden wissenschaftlichen Erkenntnis sen, zeichnen dieses Buch im Besonderer aus en Schlussendlich ist dieses Buch geschrieben um im klinischen Alltag zu unterstutzen und zu helfen. Es enthalt Aspekte der arztlicher wie der pflegerischen und der physiothe rapeutischen Arbeit, was sich auch in de Auswahl der Co-Autoren widerspiegelt. De Gesamteinfluss des Buches wird grolBser seir als seine einzelnen Kapitel, Obwohl das Buc ein alltagliches Thema zu behandeln scheint emptehle ich es jedem, der sich mit Tho raxdrainagen in seiner klinischen latigkei y beschäftigt, der seine Arbeit für den Patien 2- ten durch Fokussierung aut die eintachen täglichen Routineabläufe erheblich verbes sern m']","['lichen Arbeit helfen, die für sich genommen jedoch nicht die grolse Aufmerksamkeit genie(βsen, können in ihre Addition einen signifikanten Einfluss auf da: Gelingen haben. Dieses Buch ist einzigartic in der einfachen, ehrlichen und praktischer Herangehensweise an das Thema,Thorax drainagen"" Das Buch stellt das Thema umfassend dar Es umfasst die Themenfelder Anatomie, Phy siologie, Indikationen, Art der Drainagen, Le gen einer Drainage, Komplikationen, Pflege Management des Pleuraspaltes, Schmerz therapie, Physiotherapie und Entfernen der Drainage. Ich habe viel gelernt, und ich wette dass jeder Thoraxchirurg, egal wie ertahrer er sein mag, in diesem Buch viele Dinge fn den wird, die interessant, uberraschend ung hilfreich sind und die ihm helten, seine Arbei für und mit den Patienten zu verbessern Einzigartig ist das Buch auch darin, sich durchgängig auf das zu beziehen, was wi aufarund wissenschaftlicher Arbeit wissen Ganz besonders im Umgang mit Thoraxdral nagen ist die Vorgehensweise der Klinike\n\nditionen, die vorhandene wissenschaftliche Evidenz tritt zumeist in der Hintergarunc Dieser Bereich illustriert sehr qut die Beob achtung von Stuart Chase, die er bereits 1888 gemacht hat: ,Für die, die glauben, brauch es keinen Beweis, für die, die nicht qlauben ist kein Beweis möglich"". Trotz der doama tischen Glaubensarundsätze und Lager di existieren, gibt es eine groBe Zahl seriöser Daten. Einige der wissenschaftlichen The men sind sicherlich noch nicht umfassend aufaearbeitet. aber Thomas Kiefer hat die existierenden wissenschaftlichen Frkennt nisse gründlich aufgearbeitet. Er hat diese Erkenntnisse an ieder Stelle in einer qut les baren, einfachen Art und Weise eingebracht immer offen und ehrlich betonend., was wi wissen und was wir nicht wissen. Dies führ dazu, dass er einige der häufig zitierten Dod men entlarvt-er tut dies in einer einfacher an Fakten orientieren und sachlichen Ar und Weise. Dieser autrichtige und sachliche Stil der Diskussion und das sich daraus er gebende Management, basierend auf der vorliegenden wissenschaftlichen Erkenntnis sen, zeichnen dieses Buch im Besonderer aus en Schlussendlich ist dieses Buch geschrieben um im klinischen Alltag zu unterstutzen und zu helfen. Es enthalt Aspekte der arztlicher wie der pflegerischen und der physiothe rapeutischen Arbeit, was sich auch in de Auswahl der Co-Autoren widerspiegelt. De Gesamteinfluss des Buches wird grolBser seir als seine einzelnen Kapitel, Obwohl das Buc ein alltagliches Thema zu behandeln scheint emptehle ich es jedem, der sich mit Tho raxdrainagen in seiner klinischen latigkei y beschäftigt, der seine Arbeit für den Patien 2- ten durch Fokussierung aut die eintachen täglichen Routineabläufe erheblich verbes sern m']",这本书涵盖了胸腔引流的各个方面，包括解剖学、生理学、适应症、引流类型、引流的优势、并发症、胸膜裂管理、疼痛治疗、物理治疗和引流拔除。书中还强调了对现有科学证据的运用，并通过简单、真诚和实用的方法介绍了这一主题。,simple,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
抗菌药物在脓毒症和脓毒性休克的治疗中扮演着怎样的角色？,抗菌药物在脓毒症和脓毒性休克的治疗中扮演着怎样的角色？,['体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�'],['体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�'],抗菌药物在脓毒症和脓毒性休克的治疗中扮演着重要的角色。多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患者的发病率和病死率。因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药或者联合治疗。联合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。,simple,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"How should ICU patients with sepsis undergo fluid resuscitation and vasopressor therapy, including specific protocols or medications?","How should ICU patients with sepsis undergo fluid resuscitation and vasopressor therapy, including specific protocols or medications?","[' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,"", ""; Alain Cariou, MD; Jean- Dhainaut, MD, PhD; Simon Finfer, MD; Francois Juan Gea-Banacloche, MD; Herwig Gerlach, MD. PhD: Maurene A. Harvey. RN. MPH: Steven M Hollenberg, MD; Ronald V. Maier, MD: John J. Marini, MD; Martin Nitsun, MD; Graham Ramsay, MD: Jonathan E. Sevransky, MD; Joseph W. Szokol, MD. MD; Christophe Vinsonneau,\n\n### REFERENCES\n\n1. Dellinger RP: Cardiovascular managemen of septic shock. Crit Care Med 2003: 31 946-955 Friedman G. Silva E. Vincent JL: Has the mortality septic changed with : shock time? Crit Care Med 1998: 26:2078-2086 Sackett DL: Rules of evidence and clinica recommendations on the use of antithrom botic agents. Chest 1989: 95:2S-4s Sprung CL. Bernard GR. Dellinger RP: In troduction. Intensive Core Med 2001 27(Suppl):S1-S2 Rivers E Nouven B. Havstad S et al: Earls goal-directed therapy in the treatment of severe sensis and septic shock. N EnalJMed 2001: 345:1368-137' Weinstein MP. Reller LP., Murphy JR, et al The clinical significance e of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia adults. I. Laboratory and epidemiologic ob servations. Rev Infect Dis 1983: 5:35-5:3 7. Blot F. Schmidt E. Nitenberg G. et al: Ear lier positivity of central venous versus pe- ripheral blood cultures is highly predictive of catheter-related sepsis.J Clin Microbio 1998:36:105-109 Mermel LA. Maki DG: Detection of bactere mia in adults: Conseguences of culturing ar inadequate volume of blood. 1.Ann Inter Med 1993: 119:270-275 McCabe WR. Jackson GG: Gram negative Intern Med 1962: : 110 bacteremia. Arch 92-100 10. Kreger BE. Craven DE, McCabe WR: Gram ⅣV. Re-evaluation negative bacteremia. clinical features and treatment in 612 pa tients. Am J Med 1980: 68:344-355 11. Leibovici L. Shraga I. Drucker M. et al: The benefit of appropriate  empirical antibiotic treatment in patients with bloodstream in fection. J Intern Med 1998: 244:379-386 Ibrahim EH. Sherman G. Ward S. et al: The influence of inadequate antimicrobial treat ment of bloodstream infections on patien outcomes in the ICU setting. Chest 2000 118:146-155 13. Hatala R, Dinh T. Cook DJ: Once-daily ami noglycoside dosing in immunocompetent adults: A .meta-analysis S. Ann Intern Mec 1996;124:717-725 14. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of ami * Dis 1997: noglycosides. Clin Infect 796-809\n\nCrit Care Med 2004 Vol. 32, No. 3\n\n15. Amsden GW, Ballow CH. Bertino JS: Phar and Pharmacodynamcis of macokinetics Anti-infective Agents. In: Principles and Fifth Edi Practice of Infectious Diseases. tion. Mandell GL. Bennett JE. Dolin F (Eds), Philadelphia, Churchill Livingstone 2000, pp 253-261 Hvatt JM. McKinnon PS. Zimmer GS, et al The importance of pharmacokinetic/phar- : surrogate markers to macodvnamic out comes. Focus on antibacterial agents Clir Pharmacokinet 1995: 28-143-160 17 Jimenez MF, Marshall JC: Source control ir the management of sensis. Intensive Care Med 2001: 27:S49-S62 Bufalari A. Giustozzi G. Moggi L: Postoper- ative intraabdominal abscesses: Percutane treatment Acto Chis surgical ous versus Bela 1996: 96:197-200 Moss RL. Musemeche CA Kosloske AM: Ne crotizing fascitis in children: Prompt recog nition and aggressive therapy improve sur vival. J Pediatr Surg 1996: 31:1142-1146 Centers for Disease Control and Prevention Guidelines for the Prevention of Intravascu lar"", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence""]","['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��推荐对可能有特定感染源的脓毒症患者，应尽快明确其感染源，并尽快 采取适当的控制措施 (BPS)。\n脓毒症和脓毒性休克的感染源控制原则是感染部位的快速诊断和及时处理。对易于清除 的感染灶，包括腹腔内脓肿、胃肠道穿孔、胆管炎、胆囊炎、肾盂肾炎伴梗阻或者脓肿、肠缺 血、坏死性软组织感染和其他深部间隙感染(如脓胸或者严重的关节内感染)，应在初始复苏 后尽快控制感染灶，普通诊断后不超过 6-12 h 。当血管内植入装置为疑似感染源时，拔除 导管可能是有益的。\n7.3 血管活性药物\n如有侵权请联系网站删除\n推荐意见 18：推荐去甲肾上腺素作为首选血管加压药(强推荐，中等证据质量)；对于 快速性心律失常风险低或者心动过缓的患者，可将多巴胺作为替代药物(弱推荐，低证据质量)。\n去甲肾上腺素通过其缩血管作用而升高 MAP，对心率和每搏输出量的影响小，可有效 改善脓毒性休克患者的低血压状态。多巴胺主要通过增加心率和每搏输出量升高 MAP，可 能对心脏收缩功能受损的患者疗效更好，但可能引起心动过速，增加患者心律失常的风险。\n一项纳入11项随机试验的比较去甲肾上�', 'RT 需求、 尿量、生存期、住院时间、 心律失常发生率等疗效指标均无显著改善。 我国相关研究表明， LDD 不能降低脓毒症急性肾衰竭患者 RRT 需求及病死率。\n推荐意见 21 ：经过充分的液体复苏以及使用血管活性药物后，如果仍持续低灌注，建 议使用多巴酚丁胺(弱推荐，低证据质量)。\n多巴酚丁胺作为一线正性肌力药，为 EGDT 临床试验标准治疗的一部份，在其使用中 未发现对病死率的不良影响。 两项 ICU 脓毒症患者的大型前瞻性临床试验显示，使用多巴 酚丁胺将患者心输出量提高至高于正常水平不会改善临床结局。然而， 一些患者可能通过正 性肌力药物改善组织灌注，增加氧气输送。我国一项评价多巴酚丁胺联用去甲肾上腺素治疗 脓毒性休克伴顽强性低血压的研究表明，多巴酚丁胺可有效升高血压， 改善循环与灌注，提 高救治成功率。\n推荐意见 22：建议所有需要血管活性药物的患者置入动脉导管进行连续性血压测定(弱 推荐， 极低证据质量)。\n在休克状态， 使用动脉导管监测血压比袖带血压计测量更准确，可进行连续监测且允许\n如有侵权请联系网站删除\n每搏分析，有助于医务人员更准确']",nan,negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
你觉得在何种情况下应该推荐使用非侵入式呼吸机？,你觉得在何种情况下应该推荐使用非侵入式呼吸机？,"['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', '重脓毒症与脓毒性休克治疗国际指南_p15_f2.png)\n\nPEEP, positive end-expiratory pressure: F/TV, frequency/tidal volume; SBP, ,systolic blood pressure: MV, mechanical ventilation ""Options include T-piece. continuous positive airway pressure 5 cm H-O. or low-level (5-10 cm H₂O typically based on endotracheal tube size) pressure support ventilation (78-80, 135)\n\n', 'ochte und der sich nicht nur auf die glamourösen"" Themen konzentrieren wil te,\n\nDer Anaesthesist 7 2017\n\n', 'ressor agents); c) no new po- d) low tentially serious conditions; ventilatory and end-expiratory pressure e) requiring levels of requirements: and F102 that could be safely delivered with a face mask or nasal cannula. If the spon- breathing trial is successful taneous consideration should be given for extu- Appendix bation (see D). Spontaneous breathing trial options n include level of pressure continu- support with ous positive airway pressure 5 cm H.O or a T-piece\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nRationale. Recent studies demonstrate that daily spontaneous breathing trials the c duration of mechanical ventilation ducet (78-80). Although these studies had limited of patients with documented ALI/ numbers ARDS. believe that there is to no reason different out- ALI/ARDS patients would have comes from other critically ill patients. Suc- breath- cessful completion of spontaneous of a high likelihood trials leads to ing discontinuation of successful mechanical ventilation.\n\n### L. Sedation, Analgesia, and Neuromuscular Blockade in Sepsis\n\n1. Protocols should be used when sedation of critically ill mechanically ventilated patients is required. The protocol should include the usec of a sedation goal, ,mea- a standardized subjective sured by seda- tion scale.\n\nR\n\nRationale (Ll and L2). Mechanically ven- tilated patients receiving continuous sedation duration of a significantly have longer may mechanical ventilation as well as ICU and hos- pital length of stay (81). A daily interruption or ""continuous"" sedative infusion lightening of a patient is awake the until the may decrease 1 ICU duration of and ventilation mechanical (82). The sedation stay use  protocols in mechanically ventilated patients has shown a duration of reduced Iventilation, mechanica. length of stay, and tracheostomy rates (83).\n\nblockers should be 3. Neuromuscular avoided if all possible in the septic patient due to the risk of prolonged neu- blockade following discon- romuscular tinuation. If blockers neuromuscular than the first must be e used for longer hours mechanical ventilation, either intermittent bolus as required or contin uous infusion with monitoring of depth of block: with train of four rmonitoring should be used\n\nRationale. Prolonged skeletal muscle n critically ill weakness has been reported in patients following the use of intermediate- and long-acting neuromuscular blockers (84-91). The risk of prolonged be re- paralysis may\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nof the duced if an intermittent assessment depth blockade is of neuromuscular per- formed (92, 93),\n\n### M. Glucose Control\n\n1. Following initial stabilization of patients with severe sepsis, maintain blood glu- <150 mg/dL (8.3 mmol/L). Studies cose the role e of glycemic control supportingt have used continuous infusion of insulin and glucose. With this protocol, glucose should be monitored frequently after ini 30-60 tiation of the protocol (every mins) and on a regular basis (every 4 hrs. the blood glucose concentration once has stabilized\n\noiuue Rationale. A large single-center trial of showed signit postoperative e surgical patients icant improvement in I survival when continu- ous infusion insulin  was used to maintair 80 and 110 mg/dL (4.4-6.1 glucose between (94). Exogenous glucose was begun mmol/L) simultaneously with insulin with frequent monitoring of glucose (every 1 hr) and inten- sity of monitoring greatest at the time of ini- tiation of insulin. Hvpoglvcemia 1may occur There is 1 no reason to think that these data are not generalizable to all severely septic pa- tients. Post hoc data analysis of the trial data revealed that although best results were ob- glucose was maintained between tained when: 80 and 110 mg/dL (4.4 and 6.1 mmol/L) <150 mg/dL (8.3 mmol/L achieving a goal of < also improved outcome when compared with This goal will likely higher concentrations.T reduce the risk of hypoglycemia. The contro. of the blood glucose concentration appears to be more important than the amount of insulin infused (95, 96). The frequency of blood glu cose determinations may require the use of central or arterial catheters for blood sam pling\n\n2. In patients with severe sepsis, a strategy of glycemic control should include a nu- trition protocol with the preferential use of the enteral route.', '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-']","['                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ', '                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ']",nan,negative_rejection,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
在脓毒性休克多药联合治疗中，哪些因素需要考虑以优化抗菌药物的剂量？,在脓毒性休克多药联合治疗中，哪些因素需要考虑以优化抗菌药物的剂量？,"['superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion', "" require agents more be rapidly infused whereas others can administered as a bolus.\n\nCrit Care Med 2004 Vol, 32. No. 3\n\nhave activity against the likely pathogens fungal) (bacterial and that penetrate The the into sepsis. presumed source  the drugs should be choice of c guided by susceptibility patterns of microorganisms in the community and in the hospital.\n\nRationale. The choice of empirical antibi- otics dependse on complex issues related to the patient's history (including drug intolerance), the clinical syndrome, underlying disease, and patient's com- patterns in the susceptibility munity and in the healthcare facility.\n\nThe initial selection of fan empirical anti- microbial regimen should be broad enough according to these criteria, covering all likely pathogens since there is little margin for error in critically ill patients. There is ample e evi- dence that failure to initiate appropriate ther- therapy that is promptly (i.e..t s active anv against the causative pathogen) has s adverse on outcome (9-12) consequencese Although restricting the use of antibiotics and particularly broad-spectrum antibiotics. is important for limiting superinfection and for antibiotic- the development of decreasingt resistant pathogens, patients with severe sep or r septic shock y warrant broad-spectrum until the causative. n and its therapyt organism antibiotic susceptibilities are defined. At that point, restriction of the number of antibiotics and narrowing the spectrum of antimicrobia therapy is an important and responsible strat- for minimizing the development of resis egv 1 tant pathogens and for containing costs All patients should receive a full loading dose of each antimicrobial. However, patients with sepsis or septic shock often have abnor- mal renal or hepatic function and may have abnormal volumes of distribution due to ag gressive fluid resuscitation. The ICU pharma- cist should be consulted to ensure that serum concentrations are attained that maximize ef- ficacy and minimize toxicity. (13-16).\n\nE\n\nDIauL Rationale. Use of antimicrobial agents with the and reducing a more spectrum narrow e the likelihood duration of therapy will reduce the that develop superinfection patient with or resistant organisms such pathogenic difficile, on Candida species, Clostridium Enterococcus faecium. vancomvcin-resistant However, the to minimize superinfec- desire tions and other complications should not take the need patient give the precedence over e course of potent antimicrobials. an adequate\n\n4. If the presenting clinical syndrome is be due determined to a noninfec tious cause, antimicrobial therapy should be stopped mini- promptly the of development mize resistant and superinfection with pathogens other pathogenic organisms.\n\n### E Grade\n\nRationale. Clinicians should be cognizant blood that be the cultures negative sepsis or septic shock majority cases Thus, the to continue, decision narrow. be made stop antimicrobial therapy must on the basis of clinician judgment and other cul- ture results.\n\n### D. Source Control\n\n1. Every presenting with patient 1severe sepsis should be evaluated for the pres- ence of a focus on infection amenable to measures, specifically control source the drainage of an abscess or local focus of in- debridement on infection, the fected necrotic tissue, the removal of a or the defin potentially infected device, itive control of a source of ongoing mi- crobial contamination (17). (See Appen- dix A for of potential sites examples needing source control.)\n\nE Grade\n\n### Grade\n\nRationale. Case series and e expert opinion support the principle that rapid correction of a source of microbial contamination is essentia survival of the severely septic maximize with acute physiologic patient deterioration.  fol- Intervention should only undertaken and lowing resuscitation. Timely adequate particularly impor- emergent intervention is tant for patients with necrotizing soft tissue intestinal ischemia (19). infection or 1\n\n4. If intravascular access devices are poten- tially the source of severe sepsis or septic shock, they should be promptly removed after establishing other vascular access.\n\n### E Grade\n\nRationale? Intravascular access o devices are be of the majority of thought to the source nosocomial bloodstream infections. When pa- develop sepsis tients unknown source, be to leave reasonable vascular may access of infection devices in place until the e source can be determined. However, when patients have severe sepsis or septic shock of unknown source, clinicians should consider remova and replacement of vascular access  devices to be a priority, even if the device is tunneled or surgically implanted (20, 21).\n\n### E. Fluid Therapy\n\n"", ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,"", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-', ' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(']","['�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�']",在脓毒性休克多药联合治疗中，需要考虑以下因素以优化抗菌药物的剂量：肝肾功能不全的风险、未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多数抗菌药物的分布容积变大，导致多数患者体内抗菌药物水平未达到预期，因此，这些患者的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监测。,negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
在中国的ECMO治疗中，医疗资源配置扮演着怎样的角色？,在中国的ECMO治疗中，医疗资源配置扮演着怎样的角色？,"['    |\n|  9 | nan  | Frühe trophische/hypokalorische enterale Ernährung                                                     | Frühe trophische/hypokalorische enterale Ernährung                                                                                                                                             | Schwache Empfehlung                    |\n| 10 | nan  | nan                                                                                                    | nan                                                                                                                                                                                            | nan                                    |\n| 11 | nan  | nan                                                                                                    | Keine Omega-3-Fettsäurer                                                                                                                                                                       | Evidenz moderat                        |\n| 12 | nan  | nan                                                                           ', "" Catheter-Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732"", "" with categori zation previouslye described (Table as adapted from Ref. 3). The this e methods for document build on a 2001 publication spon- sored by the International Sepsis Forum and use the same method of grading recommen. dations (4). The supplement submission wil include background material, questions posed that led to the recommendation, and expanded rationale. This executive summary is targeted to be concise and user friendly for the bedside clinician, The 2001 publication that was s used as a starting point for current : process included a MEDLINE search for clinical trials in the preceding 10 vrs. supplemented by manual search of other relevant journals, Sub topics for each recommendation were cross referenced to sepsis, septic sepsis, severe shock. sepsis syndrome, and infection. The Surviving Sepsis Campaign guidelines consid ered the in the 2001 evidence 1 publication (through 1999) and repeated the process for 2000 through 2003. The committee process began in June 2003 with a meeting featuring the first presentations of data and recommen dations. Recommendations discussed were and critiqued. Each clinical trial used to sup port recommendations was graded based lor the methodology in Table 1 and included pres- ence or absence of important elements such as concealed randomization, blinded outcome adjudication, intention to treat analysis, and explicit definition of primary outcome. All ar- v reviewed ticles were initially based on sub- group assignments and d typically by  two on three participants. Survival (28-30 days) was the standard outcome measure used to assess outcome benefit, and when an alternative was used this is the rationale. Where $ stated in strong trial evidence existed for outcome ben- efit in critically ill populations known to con tain a larger number of sepsis patients, these trials were considered in determination of rec ommendation grading. A strict evidence-based methodology with a scoring system was\n\nused. The goal was total consensus, which wa: reached in all recommendations except two. In those circumstances (recommendations C3 ang H1), the solution was achieved with the inclu subrecommendations that expressed some difference in expert opinion, When there difference of opinion was 1about grading clinical trial, an outside epidemiologist was con sulted This occurred in one circumstance with resolution of differences. Each participant com pleted a conflict of interest form, and individual: were not assigned to a subgroup topic if they had a potential conflict of interest. A full listing of al potential conflicts of interest is included with this article. Following that meeting. the process continued with o further refinement t of recom mendations through electronic communicatior among committee members. A second meeting of core members of the committee occurred inr early October 2003. The document was finalized and approved by the consensus committee and by sponsoring organizations in December 2003 Evidence-based anproaches more readily applied to data from therapeutic trials 1 of diagnostic techniques is less Evaluation well suited to this approach. Readers will note that the maiority of the recommendations ar nof supported by high-level evidence. Most are supported by expert opinion only. In order fo a general recommendation to carry a higher level of evidence (grades A. B. C. or D). a supporting study or studies must have shown a clinical outcome difference. Studies showing physiologic changes that could be potential sur of clinical outcome benefit were rogates e not used by themselves as pivotal studies but were used to support the validity of studies showing an outcome in a clinically important variable such as survival or length of ICU stay. A grade o A, B, or C required randomized trials. Recom mendations are graded and followed with ratio nale. References are provided to support grades A-D. In the committee's deliberations, the grad i did not establish the ing of a recommendation level of priority or importance of a specific in tervention, only the degree of literature support Pediatric considerations are provided at the end of the document for aspects of management that differ from 1adults. Recommendations are grouped by category and not by hierarchy\n\n### A. Initial Resuscitation\n\n1. The resuscitation of a patient in severe sepsis or sepsis-induced tissuel hypoperfu lactic acidosis sion (hypotension or should begin as soon as the syndrome is should be not and delayed recognized pending ICU admission. An elevated se- concentration identifies tis- lactate rum sue hypoperfusion in patients at risk who are not hypotensive. During the first 6 hrs the goals of initial resus- of resuscitation, t citation of sepsis-induced hypoperfusion should include all of the following as one part of a treatment protocol:\n\nCentral venous pressure: 8-12 mm I Hg Mean arterial pressure ≥65 mm Hg Urine output ≥0.5 mL-kg .hr-1 Central venous ("", ' | nan                                    |\n| 26 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n| 27 | nan  | EIO inspiratorische Sauerstofffraktion HEOv higb frequency oscillatory ventilation"" Glgastrointestinal | nan                                                                                                                                                                                            | nan                                    |\n\nBPS Best Practice Statement, Ha Hämoglobin, FFP Fresh Frozen Plasma, PEEP positive endexpiratory pressure"", paO2 arterieller Sauerstoffpartialdruck FIO  inspiratorische Sauerstofffraktion, HFOV.high frequency oscillatory yentilation"" Gl gastrointestina\n\nWeiterhin wird unverändert von der Anwendung von Hydrokortison bei sep- tischem Schock abgeraten, wenn man durch Volumen- und Vasopressorthera- pie eine hämodynamische Stabilität zielen kann; falls dies nicht gelingt, , wird die Gabe von Hydrokortison in einer Ta- gesdosis von 200 mg empfohlen. Die Gabe von Selen wird gemäf den deutschen SISPCT-Studie als Daten dere ,strong recommendation"" nicht empfoh- len [19].\n\n### Ernährung\n\nIn der aktuellen Version der Leitlinien ist der Stellenwert der enteralen Ernährung\n\nder gegenüiber Ernährung parenteralen l Eine frühe mehrfach betont: enterale hypo- Ernährung, bzw. trophisch auch Neu ist wird klar favorisiert kalorisch, mit niedri- eine schwache Empfehlung ger Evidenz zum Einsatz postpylorischer bei mit Patienten Ernährungssonden Aspi- oder hoher Ernährungsintoleranz rationsgefahr. Neu sind die Stellungnah Zu Omega-3-Fettsäuren, Arginin men Glutamin, empfohlen welche nicht unde der Neu  aktuellen Version werden. ist a', ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence""]","['2018年的统计数据显示,中国人ECMO 的使用率为0148/10万居民年而其他国家的数据 显示在资源充足情况下ECMO使用率应为(0.3- 05)/10万居民年。与此相比,中国仍有很大的发 展空间。一方面,这与ECMO设备保有量不足相 关随着2019年底新冠疫情县发重症病例逐浙增 多可用的ECMO设备体现出了明显的不足. 据不 金统计当时金国ECMO存量仅约400台远 不能满足临床需: 要但今人欣喜的是,以此为契 机在国家政策的鼓励下国产重医疗器村自主 化研制如火如茶展开,很快有望打破该设备长期以 来依赖进口价格高昂的局面另方面ECMO 专业技术人员的短缺也是ECMO开展例数过少的 重要原因:根据CSECIS的统计武汉新冠脑炎是 发期间共有79个ECMO团队对重症新冠肺炎惠者 进行ECMO支持治疗,但其中51个EMCO团队是为 了应对新冠危机临时组建的,并且21个团队在此 之前从未开展过ECMO支持。由于ECMO是一科 复杂目高风险的治疗方法,充分的培训和大量的经 验是必不可少的。 、武汉新冠疫情暴发初期血的教 训充分说明了缺乏经验的ECMO项目必定会导致 不利后果。笔者团队对武汉初期在11家定点医院 的79个ECMO团队进行ECMO支持的新冠肺炎惠 者的回顾性分析发现,患者的死亡率高达71.6% 血2018年全国的数据显示VV-ECMO的死亡率仅 为29.1%.', '这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '展18260例,累计总共) 展ECM0154106例,54%的患者可存活至出院或转 从ECMO中心分布上看,ECMO中心尤其是 高水平的ECMO中心,主要集中于北美\n\n近年来,ECMO在中国大陆地区同样发展迅 猛,ECMO中心及开展ECMO的例数均有明显增 加,中国医师协会体外生命支持专业委员 (CSECLS)第四届中国体外生命支持年会上布的 数据显示,2020年共有500家ECM0中心上报数 据共开展ECMO患者6937例较2019年增加 6.3%。在患者人群与适应证方面,成人患者占绝大 数,成人接受呼吸、心脏辅助患者的生存率分别 达到54.5%和51.6%,与ELS0数据相当但体外心 肺复苏(ECPB)患者生存率仅为27.6%. 随着ECMO开展例数的逐渐增加,接受ECMO 支持患者的流行病学和临床特征,影响患者死广的 危险因素及社会经济影响等逐渐被揭示为后 :结 ECMO患者适应证的选择,判断患者预后等起到重 要作用(8-11] 然而虽然从2017年开始国内ECMO 开展例数明显增加,但国内尚无准确客观的统计 资料详细描述ECMO患者的流行病学及预后情况 CSECLS虽然收集每年国内ECMO中心和开展例 数、死亡率等相关信息,但缺乏更加客观、详尽的统 计,不能为后续ECMO的发展提供进一步的指导。 笔者团队在国家卫生健康委员会领 面导下对 2018年全国1700家三级医院接受ECMO治疗患者 的临床及预后信息进�']",医疗资源配置在中国的ECMO治疗中扮演着至关重要的角色。ECMO技术的实施需要大量的卫生资源，包括设备、人员和经验。然而，中国在ECMO设备保有量、专业技术人员的培训与经验积累方面存在不足。部分基层医疗中心跟风上马ECMO项目，但适应证把控不严格，管理不规范，导致医疗花费巨大，患者预后不佳。此外，ECMO中心的分布不均衡，地域差异明显，高水平的ECMO中心主要集中于特定地区，而较小的中心存在质量控制水平不足的问题。因此，合理配置医疗资源、提高中心的质量控制水平以及建立多中心的区域中心是提高ECMO治疗成功率和保障患者安全的重要举措。,negative_rejection,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
在感染性休克患者治疗中，重组人活化蛋白C（rhAPC）的使用建议是什么？,在感染性休克患者治疗中，重组人活化蛋白C（rhAPC）的使用建议是什么？,"[""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '��疗的心源性休克\n\n患者的左心室减压与较低的死亡率相关。 而 VA-ECMO期间左心室减压的时机、最佳减压方式 如何选择[23]?(5)最近的研究表明,对于脓毒症合并 脓毒症心肌病,存在严重心功能障碍、心源性休克 惠者,使用VA-ECMO可降低病死率,然而该研究为 回顾性、观察性研究,且多聚焦于脓毒症引起的左 心收缩功能障碍。 对于脓毒症相关的右心 小全心功 能障碍,是否可应用ECMO支持?对于心输出量正 常或相对偏高,但存在严重血管张力不足的患者可 [24-25] )。(6)神经 否应用VA-ECMO支持目前尚无定论 统并发症严重影响ECMO患者的短期和长期预 后,尤其是ECPR患者,ECMO运行过程中如何进行 脑功能监测?如何及早识别神经系统预后不佳的 患者以免不必要的长期ECMO支持,避免增加不义 要的医疗花费和患者痛苦(26-27]?关于ECMO技术还 有更多未知值得进一步探索 索研究 综上,ECMO技术目前在中国蓬勃发展,但与 发达国家相比仍存在巨大差距,自面临着区域发展 不均、区域化ECMO中心不完善以及ECMO学科建 设等方面的诸多问题,但随着对该技术认识的不断 进步和国家行政部门对未来发展方向的把控,相信 ECMO在中国一定能够得到长足发展,切实改善患 者预后 利益冲突作者声明不存在', '这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '��推荐对可能有特定感染源的脓毒症患者，应尽快明确其感染源，并尽快 采取适当的控制措施 (BPS)。\n脓毒症和脓毒性休克的感染源控制原则是感染部位的快速诊断和及时处理。对易于清除 的感染灶，包括腹腔内脓肿、胃肠道穿孔、胆管炎、胆囊炎、肾盂肾炎伴梗阻或者脓肿、肠缺 血、坏死性软组织感染和其他深部间隙感染(如脓胸或者严重的关节内感染)，应在初始复苏 后尽快控制感染灶，普通诊断后不超过 6-12 h 。当血管内植入装置为疑似感染源时，拔除 导管可能是有益的。\n7.3 血管活性药物\n如有侵权请联系网站删除\n推荐意见 18：推荐去甲肾上腺素作为首选血管加压药(强推荐，中等证据质量)；对于 快速性心律失常风险低或者心动过缓的患者，可将多巴胺作为替代药物(弱推荐，低证据质量)。\n去甲肾上腺素通过其缩血管作用而升高 MAP，对心率和每搏输出量的影响小，可有效 改善脓毒性休克患者的低血压状态。多巴胺主要通过增加心率和每搏输出量升高 MAP，可 能对心脏收缩功能受损的患者疗效更好，但可能引起心动过速，增加患者心律失常的风险。\n一项纳入11项随机试验的比较去甲肾上�']","[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in', ' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in']",nan,negative_rejection,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
机械通气对于脓毒症患者的治疗效果如何？,机械通气对于脓毒症患者的治疗效果如何？,"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '��素与多巴胺的系统评价和 Meta 分析 (1710\n例) 不支持常规使用多巴胺治疗脓毒性休克， 研究显示，与多巴胺相比，去甲肾上腺素可降 低患者病死率并可显著降低心律失常的风险。我国一项去甲肾上腺素与多巴胺治疗脓毒性休 克的 Meta 分析显示与多巴胺相比，去甲肾上腺素可以改善脓毒性休克患者的血流动力学，\n降低患者的病死率。\n推荐意见 19：建议在去甲肾上腺素基础上加用血管加压素(最大剂量 0 .3U／min) 以 达到目标 MAPP 或者降低去甲肾上腺素的用量(弱推荐，中等证据质量)。对于脓毒性休克患 者，推荐在血管活性药物使用的基础上加用参附注射液以增加提升血压的效果、稳定血压和 减少血管活性药物用量(强推荐，中等证据质量)。\n脓毒性休克患者体内血管加压素水平低于休克状态的预期水平。小剂量血管加压素     (0.03U／min)用于其他升压药治疗无效的脓毒性休克患者，可提高 MAPP 或者减少去甲肾 上腺素的用量。 VASTT 研究结果显示，单用去甲肾上腺素组与联用血管加压素 (0.03U/min) 组患者 28 d、 90d病死率及严重不良事件发生率差异无统计学意义，亚组分析显示，病情 较轻 (随机时接受＜15μg/min 去甲', '��疗的心源性休克\n\n患者的左心室减压与较低的死亡率相关。 而 VA-ECMO期间左心室减压的时机、最佳减压方式 如何选择[23]?(5)最近的研究表明,对于脓毒症合并 脓毒症心肌病,存在严重心功能障碍、心源性休克 惠者,使用VA-ECMO可降低病死率,然而该研究为 回顾性、观察性研究,且多聚焦于脓毒症引起的左 心收缩功能障碍。 对于脓毒症相关的右心 小全心功 能障碍,是否可应用ECMO支持?对于心输出量正 常或相对偏高,但存在严重血管张力不足的患者可 [24-25] )。(6)神经 否应用VA-ECMO支持目前尚无定论 统并发症严重影响ECMO患者的短期和长期预 后,尤其是ECPR患者,ECMO运行过程中如何进行 脑功能监测?如何及早识别神经系统预后不佳的 患者以免不必要的长期ECMO支持,避免增加不义 要的医疗花费和患者痛苦(26-27]?关于ECMO技术还 有更多未知值得进一步探索 索研究 综上,ECMO技术目前在中国蓬勃发展,但与 发达国家相比仍存在巨大差距,自面临着区域发展 不均、区域化ECMO中心不完善以及ECMO学科建 设等方面的诸多问题,但随着对该技术认识的不断 进步和国家行政部门对未来发展方向的把控,相信 ECMO在中国一定能够得到长足发展,切实改善患 者预后 利益冲突作者声明不存在', '通气持续时间无影响，但 HFOV 组患者气压伤发生率增加。 俯 卧位通气可降低胸膜腔压力梯度，提高胸壁顺应性， 促进分泌物的清除， 从而改善 ARDS 患者的通气。对于 PaO2/FiO2＜150mmHg 的 ARDS 患者， 与仰卧位相比，在插管开始后的 前 36h内 ，每天进行 16h以上俯卧位通气可提高生存率。 包括该研究在内的 Meta 分析显 示，俯卧位治疗可降低患者病死率， 改善氧合作用。大多数患者采用俯卧位可改善氧合并可 能改善肺顺应性。\n推荐意见 29：建议使用神经肌肉阻滞剂 (NMBAs)的时间≤48h (弱推荐， 中等证据 质量)。\nNMBA 在 ICU 中最普遍的适应证是促进机械通气。研究表明， 与安慰剂相比，Pa O2/Fi O2＜150mmHg 的早期 ARDS 患者连续输注顺式阿曲库铵与生存率的改善和器官功能正常时 间的延长相关， 且未增加 ICU 获得性肌无力的风险。 合并分析3项关于 NMBA 在 ARDS 中 的作用的试验， 结果显示，短疗程 (≤48h) 连续输注 NMBA 治疗患者的死亡风险及气压伤 风险均降低。 一项关于严重脓毒症患者的RCT 显示，在深度神经肌肉阻滞期间， 氧气输送、 氧气消耗及胃黏膜 pH 值无显著改善。\n推荐意见 30：对于脓毒症导致的 ARDS，如无组织低灌注证据', 'ochte und der sich nicht nur auf die glamourösen"" Themen konzentrieren wil te,\n\nDer Anaesthesist 7 2017\n\n']","['剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']",机械通气对于脓毒症患者的治疗效果是能缩短患者机械通气时间、 ICU 住院时间及总住院时间，并可促进患者的早期活动。,negative_rejection,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
What's the recommended approach for patients unable to receive enteral nutrition?,What role does enteral nutrition play in patient management?,"['   | StressulkusStressulkusprophylaxe bei Risikofaktoren für Gl-Blutung                                     | nan                                                                                                                                                                                            | Starke EmpfehlungEvidenz niedrio       |\n|  3 | S    | Anwendung von Protonenpumpenblocker oder H2-Blocker                                                    | nan                                                                                                                                                                                            | Schwache Empfehlunc                    |\n|  4 | nan  | nan                                                                                                    | nan                                                                                                                                                                                            | BPS                                    |\n|  5 | nan  | Keine Stressulkusprophylaxe bei Patienten ohne Risiko für Gl-Blutung                                   | nan                     ', '                                                                                                                                                                       | nan                                    |\n|  6 | nan  | Keine frühe parenterale Ernährung, auch kombiniert mit enteraler Ernährung, wenn enterale              | Ernährung möalich                                                                                                                                                                              | Evidenz moderat                        |\n|  7 | nan  | falls keine enterale Ernährung möglich ist, stattdessen: i. v. Glucose und langsame Steigerung         | der enteralen Ernährung                                                                                                                                                                        | Starke EmpfehlungEvidenz moderat       |\n|  8 | nan  | nan                                                                                                    | Früher Start der enteralen Ernährung, wenn möglich                                                                                                                                             | Schwache EmpfehlungEvidenz niedrio ']","['                                                                                                                                                                       | nan                                    |\n|  6 | nan  | Keine frühe parenterale Ernährung, auch kombiniert mit enteraler Ernährung, wenn enterale              | Ernährung möalich                                                                                                                                                                              | Evidenz moderat                        |\n|  7 | nan  | falls keine enterale Ernährung möglich ist, stattdessen: i. v. Glucose und langsame Steigerung         | der enteralen Ernährung                                                                                                                                                                        | Starke EmpfehlungEvidenz moderat       |\n|  8 | nan  | nan                                                                                                    | Früher Start der enteralen Ernährung, wenn möglich                                                                                                                                             | Schwache EmpfehlungEvidenz niedrio ']","Enteral nutrition plays a significant role in patient management, with recommendations suggesting early initiation of enteral feeding if possible. If enteral feeding is not feasible, intravenous glucose should be administered with a gradual increase in enteral nutrition. This approach is supported by strong recommendations with moderate evidence.",k_context,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
What are the stress ulcer prophylaxis recommendations for severe sepsis patients?,生存性敗血症行動計劃是什麼？,"[""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence""]","[""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence""]",nan,k_context,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
What signifies sepsis based on the updated Sequential Organ Failure Assessment score change from baseline?,"这是问题：""脓毒症的诊断标准是什么？",['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],脓毒症的诊断标准是当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分时可诊断为脓毒症，也可以使用床旁快速 SOFA (quick SOFA)标准识别重症患者，见表7，如果符合 qSOFA 标准中的至少2项时，应进一步评估患者是否存在脏器功能障碍。,k_context,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
ECMO开展在国内面临哪些挑战和问题？,ECMO开展在国内面临哪些挑战和问题？,"["" sep- killer and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD"", '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '17):1583-1593 10. Holst LB. Haase N. Wettersley J. Wernerman J Aneman A. Guttormsen AB et al (2013)Transfusiot requirements in septic shock (TRISS) trial- comparing the effects and safety of liberal versu: restrictivered blood celltransfusion insepticshoc patients in the ICU: protocol for a randomised controlledtrial Trials 14:150 Damiani E. Donati A. Serafini G. Rinaldi. Adraris E. Pelaia P et al (2015) Effect of performance improvementprograms on compliance withsepsi bundles and mortality: a svstematic review and meta-analvsis of observational studies. PLOS ON 10(5)e0125821 Scheer CS. Fuchs C. Kubn SO. Vollmer M. Rehber S. Friesecke S et al (2017) Quality improvement initiative for severe sepsis andsepticshockreduce 90-day mortality: A 7.5-year observational study Crit Care Med 45(2):241-25 Bloos E. Thomas-Ruddel D, Ruddel H, Enge C, Schwarzkopf D, Marshall JC et al (2014 Impact of compliance with infection managemen quidelines on outcome in patients with severe sepsis: A prospective observational multi-cente study. Crit Care 18(2):R42 Azuhata T. Kinoshita K. Kawano D. Komatsu1 SakuraiA. Chiba Yetal (2014) Timefrom admissior to initiation of surgery for source controli a critical determinant of survival in patients wit gastrointestinal perforation with associated septi shock. Crit Care 18(3):R8: 5. ARDSNetwork (2000) Ventilation with lowe tidal volumes as compared with traditiona tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Svndrome Network. N Engl Med 342(18):1301-1308 Amato MB, Meade MO, Slutsky AS, Brochard L Costa EL, Schoenfeld DA et al (2015) Driving pressure and survival in the acute respirator distress syndrome.N EnglJ Med 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandlL Austin P et al (2013) High-frequency oscillation ir early acute respiratory distress syndrome. N Engl Med 368(9):795-805 . Frat JP, Thille AW, Mercat A, Girault C, Ragot S Perbet S et al (2015) High-flow oxygen througl nasal cannula in acute hypoxemic respiratory failure. N Engl JMed 372(23):2185-2196 .Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK Jaschinski U et al (2016) Effect of sodium selenite administration and Procalcitonin-guided therapy on mortalityin patients with severesepsis or septi shock: Arandomized clinical trial. JAMA Intern Med 176(9):1266-1276\n\n### Buchbesprechung\n\nKiefer, T. (Hrsg. Thoraxdrainager Berlin Heidelberg: Springer-Verlae Berlin Heidelberg 2016. 1., 126 S (ISBN: 978-3-662-49739-5), Softcove 39,99 EUR Es ist sehr schwer. innerhalb der Welt de thoraxchirurgischen Bücher ein neues Werk zu schaffen, das einzigartig ist. Das Buch Thoraxdrainggen iedoch herausgegeber von Thomas Kiefer erfüillt ganz klar diese Definition, Und dies aleich aus mehrerer Gründen Zu allererst ist die: ein enorm praxisori entiertes Buch Die Drainage des Pleu Thorax raspaltes und das drainagen Management vor Thoraxdrainagen sind fundamentale Bestandteil der tho raxchirurgischen Arbeit. Die Tatsache, dass diese Themen in dem Buch mit aroBer Ernst haftigkeit besprochen werden, zeugen vor seiner Intention: es will praxisorientiert seir Das Buch will in einer einfachen, praktischer Weise hilfreich sein, Einzelne einfache De tails, die bei der täg', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", ""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation.""]","['的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']",ECMO在国内面临的挑战和问题包括部分基层医疗中心跟风上马ECMO项目、适应证把控不严格、ECMO管理不规范、医疗花费巨大、患者预后不佳等。此外，ECMO技术复杂且风险高，对医疗资源配置要求高，需要占用大量卫生资源。具体实施需要一个多学科团队完成，但多学科背景造成学科归属不明确，限制了统一组织多学科合作以及相关指南与研究的推进。此外，ECMO中心的建设还需考虑每年开展的病例数以及质量控制水平等因素。,noise_robustness,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
设置肺内正压呼气结束压力有何作用和原因？,设置肺内正压呼气结束压力有何作用和原因？,"[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop', 'ochte und der sich nicht nur auf die glamourösen"" Themen konzentrieren wil te,\n\nDer Anaesthesist 7 2017\n\n', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion', ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,""]","[' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']",设置肺内正压呼气结束压力（PEEP）的作用是防止肺泡在呼气末期塌陷。通过提高呼气末正压，可以保持肺单位的开放，促进气体交换。这将增加动脉氧分压（PaO2），当应用正压呼气结束压力时，可以通过气管插管或面罩来应用。肺内正压呼气结束压力的设置应基于疾病的严重程度，并受到维持充足氧合所需的吸入氧浓度（FiO₂）的指导。一些专家根据胸肺顺应性的测量来调整床旁正压呼气结束压力，以获取最高的肺部复张。,noise_robustness,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
胰岛素治疗在 ICU 脓毒症患者中的推荐和效果如何？,胰岛素治疗在 ICU 脓毒症患者中的推荐和效果如何？,"["" Catheter-Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732"", '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome"", 'ochte und der sich nicht nur auf die glamourösen"" Themen konzentrieren wil te,\n\nDer Anaesthesist 7 2017\n\n', ' Darmde- von selektiver kontamination bzw. selektiver oraler Dekontamination sowie den Einsatz von Chlorhexidin diskutiert hatte, wurde gestrichen. Die Gründe hierfür ersatzlos sind nicht erläutert\n\n### Beatmung bei ARDS\n\ndie Weitgehend t  blieben Empfehlungen lungenprotektiven Beatmung bei ARDS. Die Basis bilden im Wesentlichen die Daten der ARDS Network-Trial mit der klaren Favorisie niedriger Tidalvolumina (6 ml/ks PBW) und einem höheren PEEP-Ni- wird favorisiert, bei 1[151. Dabei kontrollierter Beatmung e einen ,driving pressure"" unter 12-15 cm H2O anzustre ben [16] Auf Basis neuer wird Studiendaten vom Einsatz 1 Hochfrequenzbeat von mung (,high-frequency oscillatory ven tilation"") abgeraten[17]. Während in der Leitlinie von 2012 die nichtinvasive zumindest füir einen kleinen Beatmung Teil der Patienten mit sepsisinduziertem ARDS unter individueller Abwägung von Nutzen und Risiko empfohlen wur de, wird in der neuen Leitlinie explizit keine Empfehlung füir  oder gegen den von nichtinvasiver Beatmung Einsatz ARDS gegeben: sepsisinduziertem bei in diesem Zusammenhang sind auch die aktuell zur High Daten positiven Flow-Sauerstoffgabe im 1 Vergleich zul\n\nAnaesthesist 2017-66:530-538 DO110.1007/s00101-017-0299-z © Springer Medizin Verlag GmbH 2017\n\nNach vier Jahren wurde ein neues Update der internationalen Leitlinien zur Therapie durch die Surviving Sepsis der Sepsis c Campaign (SSC) veröffentlicht. Die Leitlinien wurden vollkommen neu strukturiert und umfassend bearbeitet. Sepsisspezifische TherapiemaBnahmen sowie allgemeine intensivmedizinische Malnahmen bei Sepsis sind detailliert dargestellt der Neufassung sind die Schwerpunkte c initiale Stabilisierung und die antiinfektive Therapie. Im vorliegenden Beitrag sollen die wichtigsten Neuerungen adressiert werden und so zur Lektüre der Leitlinien anregen.\n\nGuidelines Evidenzbasierte Medizin. Sepsis Schock, septischer Internationale Kooperation\n\n### International quidelines from the Surviving Sepsis Campaign. 2016 update\n\n### Abstract\n\nAn update to the international guidelines for sepsis therapy was published by the Surviving Sepsis Campaign (SSC) in March 2017. The guidelines have been completely restructured and comprehensively deal with new evidence. The quidelines discuss sepsis-specific therapeutic measures and provide c detailed recommendations on general intensive care measures for sepsis This article summarizes the most important amendments and suggests delving deeper into the guidelines.\n\nneyworus Guidelines  Evidence-based medicine Sepsis- Shock, septic-International cooperation\n\nnoninvasiven Beatmung von Bedeutung [18].\n\n### Nierenersatzverfahren\n\nNach wie vor werden intermittieren- de Hämodialyse und kontinuierliche\n\n\n|    | 0     | 1                                                             | 2                                            ', "" sep- killer and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD""]",['�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU '],在 ICU 脓毒症患者中，推荐采用程序化血糖管理方案，每 1-2 小时监测一次血糖，连续两次测定血糖大于 10mmol/L 时启用胰岛素治疗，目标血糖为 ≤10mmol/L。胰岛素治疗能使血糖水平稳定，且多项 RCTs 结果表明，与传统血糖控制相比，胰岛素强化治疗未显著降低 ICU 患者的血糖水平。,noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
微生物培养的作用是什么？,微生物培养的作用是什么？,"['e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', 'lichen Arbeit helfen, die für sich genommen jedoch nicht die grolse Aufmerksamkeit genie(βsen, können in ihre Addition einen signifikanten Einfluss auf da: Gelingen haben. Dieses Buch ist einzigartic in der einfachen, ehrlichen und praktischer Herangehensweise an das Thema,Thorax drainagen"" Das Buch stellt das Thema umfassend dar Es umfasst die Themenfelder Anatomie, Phy siologie, Indikationen, Art der Drainagen, Le gen einer Drainage, Komplikationen, Pflege Management des Pleuraspaltes, Schmerz therapie, Physiotherapie und Entfernen der Drainage. Ich habe viel gelernt, und ich wette dass jeder Thoraxchirurg, egal wie ertahrer er sein mag, in diesem Buch viele Dinge fn den wird, die interessant, uberraschend ung hilfreich sind und die ihm helten, seine Arbei für und mit den Patienten zu verbessern Einzigartig ist das Buch auch darin, sich durchgängig auf das zu beziehen, was wi aufarund wissenschaftlicher Arbeit wissen Ganz besonders im Umgang mit Thoraxdral nagen ist die Vorgehensweise der Klinike\n\nditionen, die vorhandene wissenschaftliche Evidenz tritt zumeist in der Hintergarunc Dieser Bereich illustriert sehr qut die Beob achtung von Stuart Chase, die er bereits 1888 gemacht hat: ,Für die, die glauben, brauch es keinen Beweis, für die, die nicht qlauben ist kein Beweis möglich"". Trotz der doama tischen Glaubensarundsätze und Lager di existieren, gibt es eine groBe Zahl seriöser Daten. Einige der wissenschaftlichen The men sind sicherlich noch nicht umfassend aufaearbeitet. aber Thomas Kiefer hat die existierenden wissenschaftlichen Frkennt nisse gründlich aufgearbeitet. Er hat diese Erkenntnisse an ieder Stelle in einer qut les baren, einfachen Art und Weise eingebracht immer offen und ehrlich betonend., was wi wissen und was wir nicht wissen. Dies führ dazu, dass er einige der häufig zitierten Dod men entlarvt-er tut dies in einer einfacher an Fakten orientieren und sachlichen Ar und Weise. Dieser autrichtige und sachliche Stil der Diskussion und das sich daraus er gebende Management, basierend auf der vorliegenden wissenschaftlichen Erkenntnis sen, zeichnen dieses Buch im Besonderer aus en Schlussendlich ist dieses Buch geschrieben um im klinischen Alltag zu unterstutzen und zu helfen. Es enthalt Aspekte der arztlicher wie der pflegerischen und der physiothe rapeutischen Arbeit, was sich auch in de Auswahl der Co-Autoren widerspiegelt. De Gesamteinfluss des Buches wird grolBser seir als seine einzelnen Kapitel, Obwohl das Buc ein alltagliches Thema zu behandeln scheint emptehle ich es jedem, der sich mit Tho raxdrainagen in seiner klinischen latigkei y beschäftigt, der seine Arbeit für den Patien 2- ten durch Fokussierung aut die eintachen täglichen Routineabläufe erheblich verbes sern m', '重脓毒症与脓毒性休克治疗国际指南_p15_f2.png)\n\nPEEP, positive end-expiratory pressure: F/TV, frequency/tidal volume; SBP, ,systolic blood pressure: MV, mechanical ventilation ""Options include T-piece. continuous positive airway pressure 5 cm H-O. or low-level (5-10 cm H₂O typically based on endotracheal tube size) pressure support ventilation (78-80, 135)\n\n', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�']",['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�'],nan,noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
乳酸指导复苏对脓毒性休克患者的病死率有何影响？,乳酸指导复苏对脓毒性休克患者的病死率有何影响？,"['通气持续时间无影响，但 HFOV 组患者气压伤发生率增加。 俯 卧位通气可降低胸膜腔压力梯度，提高胸壁顺应性， 促进分泌物的清除， 从而改善 ARDS 患者的通气。对于 PaO2/FiO2＜150mmHg 的 ARDS 患者， 与仰卧位相比，在插管开始后的 前 36h内 ，每天进行 16h以上俯卧位通气可提高生存率。 包括该研究在内的 Meta 分析显 示，俯卧位治疗可降低患者病死率， 改善氧合作用。大多数患者采用俯卧位可改善氧合并可 能改善肺顺应性。\n推荐意见 29：建议使用神经肌肉阻滞剂 (NMBAs)的时间≤48h (弱推荐， 中等证据 质量)。\nNMBA 在 ICU 中最普遍的适应证是促进机械通气。研究表明， 与安慰剂相比，Pa O2/Fi O2＜150mmHg 的早期 ARDS 患者连续输注顺式阿曲库铵与生存率的改善和器官功能正常时 间的延长相关， 且未增加 ICU 获得性肌无力的风险。 合并分析3项关于 NMBA 在 ARDS 中 的作用的试验， 结果显示，短疗程 (≤48h) 连续输注 NMBA 治疗患者的死亡风险及气压伤 风险均降低。 一项关于严重脓毒症患者的RCT 显示，在深度神经肌肉阻滞期间， 氧气输送、 氧气消耗及胃黏膜 pH 值无显著改善。\n推荐意见 30：对于脓毒症导致的 ARDS，如无组织低灌注证据', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�', '评估患者的休克状态，采取治疗措施。\n7.4 糖皮质激素\n推荐意见 23 ：对于脓毒性休克患者，在经过充分的液体复苏及血管活性药物治疗后如 果血流动力学仍不稳定， 建议静脉使用氢化可的松，剂量为每天 200mg (弱推荐，低证据质 量)。\n脓毒性休克患者对液体和血管活性药物治疗的反应性是选择氢化可的松治疗的重要因 素。法国一项多中心 RCT 研究结果显示，对于血管活性药无反应(液体复苏和血管活性药 治疗超过 1h，收缩压＜90mmHg)的脓毒性休克患者， 相对肾上腺功能不全患者 [定义为 最大促肾上腺皮质激素(ACTH)皮质醇增加≤ 9μg/dl] 使用氢化可的松可明显逆转休克， 降低病死率〕。两项小规模 RCTs 也显示类固醇治疗对逆转休克的作用显著。\n对于无持续休克 、死亡风险较低的严重脓毒症患者，一项大型欧洲多中心试验     (CORTICUS) 结果表明，不考虑血压对血管活性药物是否敏感的情况下，糖皮质激素未降 低患者病死率。另有研究报导，低剂量氢化可的松可逆转休克， 减轻严重脓毒症患者的炎症 反应， 改善临床状态， 但对 28d 病死率无明显改变。\n7.5   抗凝治疗\n推荐意见 24：不推荐使用抗凝血酶�', 'RT 需求、 尿量、生存期、住院时间、 心律失常发生率等疗效指标均无显著改善。 我国相关研究表明， LDD 不能降低脓毒症急性肾衰竭患者 RRT 需求及病死率。\n推荐意见 21 ：经过充分的液体复苏以及使用血管活性药物后，如果仍持续低灌注，建 议使用多巴酚丁胺(弱推荐，低证据质量)。\n多巴酚丁胺作为一线正性肌力药，为 EGDT 临床试验标准治疗的一部份，在其使用中 未发现对病死率的不良影响。 两项 ICU 脓毒症患者的大型前瞻性临床试验显示，使用多巴 酚丁胺将患者心输出量提高至高于正常水平不会改善临床结局。然而， 一些患者可能通过正 性肌力药物改善组织灌注，增加氧气输送。我国一项评价多巴酚丁胺联用去甲肾上腺素治疗 脓毒性休克伴顽强性低血压的研究表明，多巴酚丁胺可有效升高血压， 改善循环与灌注，提 高救治成功率。\n推荐意见 22：建议所有需要血管活性药物的患者置入动脉导管进行连续性血压测定(弱 推荐， 极低证据质量)。\n在休克状态， 使用动脉导管监测血压比袖带血压计测量更准确，可进行连续监测且允许\n如有侵权请联系网站删除\n每搏分析，有助于医务人员更准确']",['映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�'],乳酸指导复苏对脓毒性休克患者的病死率有显著影响，研究发现，乳酸指导复苏组患者的病死率显著下降。Meta分析结果表明，采用早期乳酸清除策略可以降低脓毒性休克患者的病死率。,noise_robustness,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
抗凝血治疗在儿童中预防DVT的有效性如何？,抗凝血治疗在儿童中预防DVT的有效性如何？,"[' Buches wird gre a critical determinant of survival in patients with gastrointestinal perforation with associated septic als seine einzelnen Kapitel. Obwohl in der einfachen, ehrlichen und praktischer shock. Crit Care 18(3):R8) ein alltägliches Thema zu behandel Herangehensweise an das Thema ,Thorax: 15. ARDSNetwork (2000) Ventilation with lowel drainagen"", empfehle ich es jedem, der sich m tidal volumes as compared with traditiona tidal volumes for acute lung injury and the Das Buch stellt das Thema umfassend dar raxdrainagen in seiner klinischen T acute respiratory distress syndrome. The Acute Es umfasst die Themenfelder Anatomie, Phy beschäftigt, der seine Arbeit für det Respiratory Distress Syndrome Network. N Engl. siologie, Indikationen, Art der Drainagen, Le: ten durch Fokussierung auf die ein Med 342(18):1301-1308 16. Amato MB, Meade MO, Slutsky AS, Brochard L täglichen Routineabläufe erheblich gen einer Drainage, Komplikationen, Pflege Costa EL, Schoenfeld DA et al (2015) Driving Management des Pleuraspaltes, Schmerz sern mochte und der sich nicht nur pressure and survival in the acute respirator therapie, Physiotherapie und Entternen der 修glamourosen""Themen konzentrie distress syndrome. NEnglJMed 372(8):747-75: 17. Ferquson ND, Cook DJ, Guyatt GH, Mehta S, HandL Drainage. Ich habe viel gelernt, und ich wette Austin P et al (2013) High-frequency oscillation in Frank C. Detterbeck MD, New h dass jeder Thoraxchirurg, egal wie ertahrer early acute respiratory distress syndrome. N Engl. Unite er sein mag, in diesem Buch viele Dinge fin- Med 368(9):795-805 18. Frat JP, Thille AW, Mercat A, Girault C, Ragot S den wird, die interessant, uberraschend unc Perbet S et al (2015) High-flow oxygen through hilfreich sind und die ihm helfen, seine Arbeit nasal cannula in acute hypoxemic respiratory für und mit den Patienten zu verbessern failure. N EnglJMed 372(23):2185-2196 Bloos F, Trips E, Nierhaus A, BriegelJ, Heyland Dk Einzigartig ist das Buch auch darin, sich Jaschinski U et al (2016) Effect of sodium selenite durchgängig auf das zu beziehen, was wil administration and Procalcitonin-quided therapy aufgrund wissenschaftlicher Arbeit wissen on mortalityin patients with severe sepsis or septii shock: Arandomized clinical trial.JAMAIntern Mee Ganz besonders im Umgang mit Thoraxdrai 176(9):1266-1276 nagen ist die Vorgehensweise der Kliniker\n\nseptic shock: The ARISE. ProCESS and ProMISe Investigators.IntensiveCare Med 41(9):1549-156 Investigators A. Group ACT. Peake SL. Delaney A Bailey M. Bellomo R et al (2014) Goal-directed resuscitation for patients with early septic shock. N EnglJ Med371(16):1496-1506 7. Mouncey PR. Osborn TM. Power GS. Harrison DA Sadique M7 Grieve RD et al (2015) Trial of early goal-directed resuscitation for septicshock. N Engd JMed 372(14):1301-1311) 8 Investigators TP (2014) A randomized trial o protocol-based careforearly sentic shock N Enal Med 370(18):1683-1693 9 Asfar P MezianiE. Hamel J-E. Grelon E. Megarbane B Anguel N et al (2014) Hiab versus low blood pressuretargetin patientswith septicshock.N Eng IMed 370(', '-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', '. internationa multicenter prospective cohortill. Am Respir Crit Care Med, 2019, 200(8) 1002-1012.DO1:10.1164/rccm.201806-109400 [23] Schrage B. Becher PM. Bernhardt A. et al. Left ventricula unloading is associated with lower mortality in patients with shocl treated with cardiogenid venoarteria extracorporeal membrane oxvgenation: : results from an international Circulation multicenter cohor studyll DO1: 142(22) 2095-2106 10.1161/ CIRCULATIONAHA.120.048792 24 WH, et al. Venoarterial Ling RR. Ramanathan K. Poor extracorporea oxygenation as mechanical membrane circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data analysis[]. Crit Care, 2021, 25(1): 246 meta-regressionr D01:10.1186/s13054-021-03668-5 [25] D, Kimmoun A. et al. Venoarteria Brechot t N, Hajage extracorporea to membrane oxygenation rescue sepsis-induced shock: cardiogenic retrospective multicentre, international cohort study ] . Lancet, 2020 396(10250):545-552. DO1 10.1016/S0140-6736(20 30733-9 [26] Ong CS, Etchill E, Dong J, et al. Neuromonitoring detects brain injury 1n patients receiving extracorporea membrane oxygenation support]]. Thorac Cardiovasd Surg, 2021 2022-02-04].  published online ahead of print October 29.2021l. DO1: 10.1016/iitcvs.2021.09.063 ([27] Hunt MF. Clark KT. Whitman G. et al. The use of cerebra NIRS monitoring to identify acute brain injury in patients with VA-ECMOIIl.I Intensive Care Med. 2021. 36(12) 1403-1409.D01:10.1177/0885066620966962\n\nELSO Member Centers EB/OL (2021-11-23 [2022-01-29] https://www elso org/Membership/ CenterMap.aspx El Sibai R. Bachir R., El Saved M. ECMO use and mortalit in adult patients with cardiogenic shock: a retrospective observational study in U.S. hospitals[ll. BMC Emerg Med 2018,18(1):20.D01:10.1186/s12873-018-0171-8 [9] Park M, Mendes PV, Zampieri FG. G et al The economic effect extracornorea membrane oxvgenation support adults with severe respiratory failure in Brazil: a  2014 hypothetica analysis[Il. Rey Bras ; Ter Intensiva 26(3):253-262.D01:10.5935/0103-507x.20140036 I J 10] Ouweneel DM Limpens Schotborgh et al. life cardiac and Extracorporeal support during arrest cardiogenic shock: a systematic review and meta-analysis [11. Intensive Care > Med 2016 42(12): 1922-1934 DO1 10.1007/s00134-016-4536-8 11] Natt BS. Desai H. Singh N, et al. Extracorporeal membrane oxygenation for ards: national trends in the United States 2008-2012Ⅲ. Respir Care. 2016. 61(10):1293-1298. DO1 10.4187/respcare.04760 [12] Cheng W. Ma XD. Su LX, et al. Cross-sectional study for the of clinical application extracorporeal membrane oxvgenation in Mainland China. 2018[ll. Crit Care. 2020 24(1):554.D01:10.1186/s13054-020-03270-1 [13] Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume extracorporea membrane and of the cases mortality Analysis oxygenation extracorporeal life support organization registry[. Am 2015. 191(8): 894-901. DOL Respir Crit Care Med 10.1164/rccm.201409-16340C [14] C, Hou X, Tong Z et al. Extracorporeal membrane oxygenation programs for COVID-19 in China[]. Crit Care 2020.24(1):317.D01:10.11', "" Catheter-Related Infections MMWI 2002: 51:1-29 O'Grady NP. Alexander M. Dellinger EP. e al: Guidelines for the prevention of intra vascular catheter-related infections. Cli Infect Dis 2002: 35:1281-1307 Choi PTL, Yip G. Quinonez LG, et al: Crys talloids ys, colloids in fluid resuscitation: A systematic review. Crit Care Med 1999: 27 200-210 Cook D. Guyatt G: Colloid Iuse for fluic resuscitation: Evidence and spin. Ann In tern Med 2001: 135:205-208 Schierhout G. Roberts I: Fluid resuscitation with colloid or crystalloid solutions in crit ically ill patients: A svstematic review o randomized trials. BMJ 1998: 316:961-964 Hollenberg SM. Ahrens TS. Astiz ME, et al Practice parameters for hemodynamic sup port of sepsis in adult patients. Crit Care Med 1999:27:639-660 LeDoux D. Astiz ME. Carpati Effects of perfusion pressure on tissue per fusion in septic shock. Crit Care Med 2000 28:2729-2732 Regnier B, Rapin M, Gory G, et al: Haemo dynamic effects of dopamine septie shock. Intensive Care Med 1977; 3:47-53 Martin C, Papazian L, Perrin G, et al: Nor- epinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993 103:1826-1831 Martin C, Viviand X, Leone M, et al: Effect of norepinepnrine on the outcome of septie shock. Crit Care Med 2000; 28:2758-2765 De Backer D. Creteur J, Silva E, et al: Ef fects of dopamine, norepinephrine, and epi nephrine on the splanchnic circulation ir septic shock: Which is best? Crit Care Med 2003:31:1659-1667 Bellomo R, Chapman M, Finfer S, et al Low-dose donamine e in patients s with earl renal dysfunction: A placebo-controlled\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsis and septic shock. N Engl J Med 1987 317:653-658 Cronin L. Cook DJ. Carlet J. et al: Cortico steroid treatment for sepsis: A critical arn praisal and meta-analvsis of the literature Crit Care Med 1995: 23:1430-1439 The Veterans Administration Systemic Sep Cooperative Study Group: Effect t or high-dose glucocorticoid therapy on mor tality in patients with clinical signs of sep sis N Enal L Med 1987: 317:659--665 Bernard GR Vincent I Laterre PE et al Efficacy and safety of recombinant humar activated protein C for severe sepsis, N Eng J Med 2001:344:699-709 Hébert PC. Wells G. Blaichman MA., et al: A multicenter. randomized, controlled clini cal trial of in critica transfusion care N Enal J Med 1999: 340:409-417 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxvgen delivery in patient: with sensis. JAMA 1993: 269:3024-3029 Lorente JA. Landín L De Pablo R. et al Effects of blood transfusion on oxvger transport variables in severe sepsis. Crit Care Med 1993: 21:1312-1318 Corwin HL, Gettinger A. Rodriguez RM, e al: Efficacy of recombinant human erythro poietin in the critically ill patient: A ran domized double-blind. placebo-controlled trial, Crit Care Med 1999: 27:2346-2350 Corwin HL. Gettinger A. Pearl RG, Efficacy of recombinant human erythropoi etin in critically ill patients. JAMA 2002 288:2827-2835 Practice parameter for the use of fresh frozen plasma. cryoprecipitate, and plate lets. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists IAM/ 1994:271:777-781 Guidelines for red blood cell and plasma transfusion for adults and children. Report of the Working CMAJ Group. 1997 156(Suppl):S1-S24 Practice guidelines for blood componen therapy. A report by the American Society of Anaesthesiologists Task Force on Blood Component Therapy. Anesthesioloqy 1996 84:732"", ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,"", ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']",nan,noise_robustness,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
为什么高证据水平的建议被认为是强烈推荐的？在这种情况下，高证据水平的建议是如何定义的？,为什么高证据水平的建议被认为是强烈推荐的？在这种情况下，高证据水平的建议是如何定义的？,"['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ', '��相关技术问题 ECMO技术虽然近年来发展迅速,但仍存在- 此尚未突破的技术难题,例如(1)患者是否能从 ECMO支持中获益?对干VV-ECMO月前仅有两项 设计严格的随机对照研究,或存在明显的设计缺 陷,或未能得出ECMO支持显著的生存获益优势: 鉴于伦理问题,自前尚未有VA-ECMO相关的临床 对照研究发表(2.18-19] (2)抗凝策略和抗凝目标如付 选择?ECMO患者的高凝状态使患者及ECMO回 路易于形成血栓,ECMO患者进行持续、全身性抗 凝治疗,以防止ECMO回路血栓形成是重症医学的 共识,但最近-篇包括21项研究(7190例接受 VV-ECMO或VA-ECMO患者)的荟萃分析显示: ECM0运行期间出血事件的发生率为17%~51%。 尤其对于创伤、存在活动性或者高出血风险的患 者,通常存在抗凝禁总证,因此抗凝策略的选择无 疑面临着巨大风险和挑战 。(3)VV-ECMO支持期 间呼吸机参数如何设置?VV-ECMO支持期间,希 望患者自身肺脏得到充分休息,避免进一步肺损 伤,但恢复到什么程度让自身肺脏工作?各个时期 的呼吸机参数如何设置目前仍无定论[21-22 。(4)目 前VA-ECMO绝大多数情况下都是经股动脉插管进 行灌注体外血流与心脏射血方向相反,这样会增 室后负荷,导致左心扩大账满,不利于心功 二经VA-ECMO�', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '                                                                                                                                                    | Starke EmpfehlungEvidenz hoch                       |\n| 14 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Schwache Empfehlunc                                 |\n| 15 | N      | nan                         | Oberkörperhochlagerung 30-45° beim beatmeten Patienter                                                                                                                                                                                                                                       | Starke EmpfehluncEvidenz niedrig                    |\n| 16 | N      | nan                         | Spontanatmungsversuche                                                                                           ', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome""]","['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ', '                                                                                                                                                    | Starke EmpfehlungEvidenz hoch                       |\n| 14 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Schwache Empfehlunc                                 |\n| 15 | N      | nan                         | Oberkörperhochlagerung 30-45° beim beatmeten Patienter                                                                                                                                                                                                                                       | Starke EmpfehluncEvidenz niedrig                    |\n| 16 | N      | nan                         | Spontanatmungsversuche                                                                                           ']",高证据水平的建议被认为是强烈推荐的，因为它们基于具有高度可信度和可靠性的证据。在这种情况下，高证据水平的建议是根据大量可靠的研究结果得出的，这些研究结果显示特定的做法或措施具有明确的效果，并且这些效果在不同的研究中得到了验证。因此，这些建议被认为是强烈推荐的，因为它们在临床实践中具有重要的价值，并且有助于改善患者的结果。,noise_robustness,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
"What defines septic shock, and how should antibiotic dosages be optimized for sepsis patients?",脓毒性休克的定义是什么？,"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��推荐对可能有特定感染源的脓毒症患者，应尽快明确其感染源，并尽快 采取适当的控制措施 (BPS)。\n脓毒症和脓毒性休克的感染源控制原则是感染部位的快速诊断和及时处理。对易于清除 的感染灶，包括腹腔内脓肿、胃肠道穿孔、胆管炎、胆囊炎、肾盂肾炎伴梗阻或者脓肿、肠缺 血、坏死性软组织感染和其他深部间隙感染(如脓胸或者严重的关节内感染)，应在初始复苏 后尽快控制感染灶，普通诊断后不超过 6-12 h 。当血管内植入装置为疑似感染源时，拔除 导管可能是有益的。\n7.3 血管活性药物\n如有侵权请联系网站删除\n推荐意见 18：推荐去甲肾上腺素作为首选血管加压药(强推荐，中等证据质量)；对于 快速性心律失常风险低或者心动过缓的患者，可将多巴胺作为替代药物(弱推荐，低证据质量)。\n去甲肾上腺素通过其缩血管作用而升高 MAP，对心率和每搏输出量的影响小，可有效 改善脓毒性休克患者的低血压状态。多巴胺主要通过增加心率和每搏输出量升高 MAP，可 能对心脏收缩功能受损的患者疗效更好，但可能引起心动过速，增加患者心律失常的风险。\n一项纳入11项随机试验的比较去甲肾上�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�']",['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较'],脓毒性休克定义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较高。,multi_context,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"How has ELSO's recommendation affected ECMO centers' yearly cases, considering regional differences, quality control importance, and COVID-19's impact on ECMO usage?",ELSO建议是如何影响ECMO中心的年开展例数？,"['的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '功率并不高。为了推动全球范围 内的ECMO技术交流与应用,在Bartlet教授推动 下国际体外生命支持组织(Extracorporeal Life Support Organization,ELSO)于1989年在密歇根大 学成立但直至2004年,全世界仅有100多家医院 开展此项工作,并且主要集中在西方发达国家。从 2008年ECMO用于成功救治甲型流感患者之后,全 球ECMO数量开始呈现快速增长趋势13 中国内地最早1例真正意义上的ECMO支持 病例始于2002年,但限于当时的经济水平、医疗条 件和医疗报销制度的限制,这一设备没有得到大范 围推广,到2015年全国ECMO中心的数量才突码 随着医疗水平的逐渐发展和医保政策的 100家。 整,中国的ECM0开始有了飞速发展。2019年底 新型冠状病毒肺炎(新冠肺炎)爆发ECMO被用干 重症新冠肺炎惠者的救治,开始进入大众视野;手) 目由于其在新冠疫情救治中起到的重要作用,国家 卫生健康委员会在《新型冠状病毒感染的肺炎诊疗 方案》中将ECMO列为危重症新冠肺炎患者的重要 救治技术,极大地促进了国内各医疗机构进一步开 展ECMO相关培训学习,成立ECMO中心(45 二、ECMO开展现状 近年ECMO临床应用突飞猛进。世界范围内 据ES0的统计数据显示,2019年全球共有488个 ECMO中心,实施ECMO的病例达到17078例,截¥ 2021年10月的统计数据显示2020年注册的ECMQ 中心数增至521个,全年开']","['的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底']","ELSO建议影响ECMO中心的年开展例数,使得ECMO中心的数量越来越多,但高质量的中心仍然以欧美发达国家为主。",multi_context,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
"How can hypoglycemia be minimized in patients without evident hyperglycemia, considering various medical treatments and pediatric care?",不考虑糖尿病患者已经明显高血糖的情况下，如何通过连续葡萄糖供应来最小化低血糖的发生？,"[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation."", ""See initial resuscitation recommendations (A1-2) for timing of resuscitation.\n\n## E Grade\n\nGrade E\n\na. Some experts prefer combination therapy for 1 patients with Pseudomonas infections.\n\nE Grade\n\nb. Most experts would use combination ther- apy for neutropenic patients with severe sepsis or septic shock. For r neutropenic patients,\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nott Williams Wilkins. Unauthorized of this article is prohibited.\n\nRationale. Healthcare professionals should engage specialists in other disciplines such as surgery, pulmonary medicine, and radiology, gastroenterology to obtain diagnostic samples and to drain, debride, e the infection or remove source as appropriate.\n\n2. The selection of optimal source control methods t weigh benefits and risks must of the specific intervention. Source con- trol interventions may further cause complications such as bleeding, fistulas, or inadvertent organ injury; in general, the intervention that accomplishes the with the e least control objective source be employed. upset should physiologic for example, consideration of percutane- ous rather than surgical drainage of fan abscess (18).\n\nRationale. Although prospective studies of of fluid resuscitation in choice patients with meta-analysis of septic shock only are lacking, clinical studies comparing crystalloid and col- loid resuscitation in general and surgical pa- tient populations indicate no clinical outcome difference between colloids and crystalloids and would appear to be generalizable to sepsis of distri- populations (22-24). As the volume bution is much larger for crystalloids than for colloids, with crystalloids re- resuscitation fluid to achieve the end : same quires more points and results in more edema.\n\n2. Fluid challenge in patients with sus- inade- hvpovolemia pected a (suspected given arterial circulation) mayl be quate at a rate of 500-1000 mL of crystalloids or 300-500 mL of colloids s over 30 mins and repeated based on response (increase in blood pressure: and urine output) and tolerance (evidence of intravascular vol- overload). ume\n\n### Grade\n\nRationale. Fluid challenge must be clearly separated from maintenance 1 an increase in fluid administration. Fluid challenge is a term used to describe the initial volume expansion period in which the response of the patient to fluid administration is carefully evaluated. amounts of fluids During t this process, large period of e administered over a short may be e the time under close monitoring to evaluate patient's response and avoid the development edema. The degree e of intravas- of pulmonary deficit in patients with severe cular volume With venodilation and ongoing sepsis varies. capillary leak, most patients require continu- fluid resuscitation during the ing aggressive first 24 hrs of management. Input is typically much greater than output, input/output and ratio is of no utility to judge fluid resuscitation needs during this time  period\n\n### F. Vasopressors\n\nRationale. Below a certain mean arterial autoregulation in various vascular pressure. and perfusion can become lin- beds can be lost, early dependent Thus. on some pa- pressure. to tients therapy t may require vasopressor achieve a minimal perfusion pressure and main flow. It is important tain adequate to supple blood pressure with ment goals such as 1 assess blood lactate ment of global perfusion such fluid resuscitation is a concentrations. Adequate f fundamental aspect of the hemodynamic : man : shock and of patients with septic agement should ideally be achievedl betore e vasopressors are used, but it is frequently necessary to employ vasopressors early as a an emergency measure in patients with severe shock (25, 26).\n\n2. Either norepinephrine dopamine (through a central catheter as soon as avail able) is the first-choice vasopressor agent to correct hypotension in septic shock.\n\nCopyrigt&肠角 ott Williams & Wilkins. Unauthorized reproduction of this article is prchibited\n\noiaue D Rationale. Although there e is no high quality primary evidence to recommend one catecholamine over another, human and an- of imal studies suggest some advantages norepinephrine and dopamine over epineph disad rine (potential tachvcardia. possibly ( eftects on splanchnic circula- vantageous tion) and phenvlephrine (decrease i 1 stroke is the adrenergic volume), Phenvlephrine agent least likelyt to produce tachycardia. Dopamine increases 1 arterial pressure mean and cardiac output,"", '-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous', 'superior vena cava) or mixed venous oxygen saturation ≥70%\n\nB\n\nRationale. Early goal-directed therapy has been shown to improve survival for emergency department patients presenting with septic shock in a randomized, controlled, single-- (5). Resuscitation directed to- center study ward the previously mentioned goals for the initial 6-hr period of the resuscitation was able to reduce 28-day mortality rate. The consen- and mixed panel judged central venous sus saturation to be equivalent oxvgen venous Either intermittent or continuous measure- ments o saturation are judged to be of oxygen acceptable. A Although lactate 1 measurement may be useful, it lacks precision as a1 measure of tissue metabolic status. In mechanically ventilated patients, a higher target central ve. of 12-15 mm Hg is pressure $ recom mended to account for the increased intratho: racic pressure. Similar consideration may be of increased ab warranted in circumstances dominal pressure. Although the cause in septic patients may be multi- tachycardia in elevated pulse with factorial, a decrease fluid resuscitation is often a useful marker of improving intravascular filling\n\n2. During the first 6 hrs of resuscitation of severe sepsis or septic shock, if central ve- mixed oxygen saturation venous nous oxygen saturation of 70% is not achieved with fluid resuscitation to a central venous of 8-12 Hg. t then transfuse mm pressure packed red blood cells to achieve a hemat ocrit of ≥30% and/or administer a dobut maximum of 20 amine infusion (up to μg-kg min ) to achieve this s goal.\n\nRationale, The protocol used in the study cited previously targeted an increase in mixed venous oxygen saturation to ≥70%. This was sequential institution of initial fluid achieved by resuscitation, then packed red blood cells, a and then dobutamine. This protocol was associated with an improvement in survival (5).\n\n### B. Diagnosis\n\n1. Appropriate cultures should always be ob- tained before antimicrobial therapy is ini- tiated. To optimize identification of caus- ative blood least two organisms, at cultures should be obtained with at least one drawn percutaneously and one drawn through each vascular access o device, un- the device was recently (<48 hrs less inserted. Cultures of other sites such 1as urine, cerebrospinal fluid, wounds, respi- fuids other body ratory secretions, or should be obtained before antibiotic ther-\n\napy is initiated as the clinical situation dictates.\n\nRationale. Two or more blood cultures are recommended (6), Ideally, at least blood one culture should be drawn through each lumen of each Obtaining vascular device. access blood cultures peripherally and through a vas- device is an important strategy. If cular access 1 both the same from organism is recovered cultures, the likelihood that the organism causing the severe sepsis is enhanced. In ad- dition, if the culture drawn through the e vas- earlier device is cular much positive access than the peripheral blood culture (i.e., >2 hrs earlier), it may offer support that the vascular device is the source of the infection (7). access Volume of blood may also be important (8).\n\n2. Diagnostic studies should be ) performed the source of the promptly t to determine infection and the causative organism.  of likely Imaging studies sampling and of infection should be per- sources formed: however, some patients may be too unstable to warrant certain invasive e of the outside procedures transport ICU. Bedside studies, such as ultrasound may be useful in these circumstances.\n\nRationale. Diagnostic studies may identify a source of infection that must be drained to max imize the likelihood of a satisfactory response to therapy. .However, even in the most organized and well-staffed healthcare facilities, transport of be patients dangerous, can placing pa- can tients in outside-unit imaging devices that are difficult to access and monitor.\n\n### C. Antibiotic Therapy\n\n1. Intravenous antibiotic therapy should be started within the first hour of rec- ognition of severe sepsis, after appropri- ate cultures have been obtained\n\nRationale. Establishing vascular access and the fluid initiating aggressive resuscitation first priority when managing patients with se- However, prompt septic shock. sepsis infusion of antimicrobial agents is also a logical strategy and may require additional vascular ac- ports. Establishing a supply of 1 premixed cess antibiotics in an emergency department or crit- for such ical care unit 1 urgent situations is an likeli- appropriate strategy for enhancing the s will be infused hood that antimicrobial agents promptly. Staff should be e cognizant that some time lengthy infusion']","[""\n\n### E Grade\n\nRationale. When a glycemic control strat- egy is initiated, hypoglycemia is minimized by providing a continuous supply of glucose sub- patient is Initially, unless the s already strate. profoundly hyperglycemia, this is accom- plished with 5% or 10% dextrose infusion and followed by initiation of feeding, preferably by the enteral route, if tolerated (97).\n\n### N. Renal Replacement\n\n1. In acute renal failure,: and in the absence of hemodynamic instability, continuous venovenous hemofiltration 1 and intermit tent hemodialysis are considered equiva- lent. Continuous hemofiltration offers eas-\n\nB Grade\n\nRationale. Studies support the equivalence of continuous and intermittent renal replace- ment therapies for the treatment of acute re nal failure in critically ill patients (98, 99).In hemodialysis termittent poorly may be hemodynamically tolerated  unstable pa- tients. There is no current evidence to support the use of continuous venovenous hemofiltra- tion for the treatment of sepsis independent of renal replacement needs.\n\n### O. Bicarbonate Therapy\n\n1. Bicarbonate of therapy for the purpose hemodynamics reducing improving vasopressor requirements is not recom- mended for treatment of hypoperfusion- induced lactic acidemia with pH ≥7.15. The effect of bicarbonate administration hemodynamics on and re- vasopressor pH as well s the at lower quirement effect on clinical outcome at any pH has not been studied\n\nRationale There is no evidence to support the use of bicarbonate the treat- therapy in hypoperfusion-induced acidemia as- ment sociated with sepsis. Two studies comparing pH saline and bicarbonate in patients with ≥7.13-7.15 failed to reveal any difference in hemodynamic variables or re- r vasopressor quirements between equimolar  concentra- e with tions of bicarbonate and normal saline either therapy (100, 101).\n\n### P. Deep Vein Thrombosis Prophylaxis\n\n1. Severe patients should sepsis recerve deep vein thrombosis (DVT) prophylaxis with either low-dose unfractionated hep- arin low-molecular r weight heparin For septic patients who have a contrain- dication for heparin I use (i.e., thrombo- active cvtopenia. coagulopathy, severe bleeding. intracerebral hemor: recent rhage), the use of a mechanical prophy- device (graduated lactic compression intermittent stockings compression device) is recommended (unless contra- indicated l the of peripheral presence disease).l vascular very high-risk In pa tients such those who o have severe sepsis and history of DVT, a combination of pharmacologic : and mechanical ther- apy is recommended.\n\n### Grade\n\nRationale. Although no study s been has performed specifically in patients with severe of benefit sepsis, large trials confirming the DVT1 prophvlaxis in general ICU populations have included significant septic numbers patients (102-104). This benefit should be ap-\n\nment of intravascular support (110). On the basis of a number of studies, it is accepted tha aggressive fluid resuscitation with crvstalloid colloids is of fundamental importance to survival of septic shock in children (111. 112) There is only one randomized, controlled tria comparing the use of colloid to crvstalloic resuscitation (dextran gelatin, lactated Ring er's solution, or saline) in children with den gue shock (111) All these children survived regardless of the fluid used but the longes time to recovery from shock occurred in chil dren who received lactated Ringer's solution Among patients with the narrowest pulse pres sure there was a suggestion that colloids wer effective than crvstalloids in restorins more normal pulse pressure Fluid infusion is bes initiated with boluses of 20 mL /ks over 5-10 mins titrated to clinical monitors of cardiae output including heart rate urine outnut capillary refill I and level of consciousness Children normally have a lower blood pressure than adults and prevent reduction in blood pressure by vasoconstrictior and in creasing heart rate Therefore blood pressu by itself is not a reliable end point for assess ing the adequacy of resuscitation, However once hvpotension occurs. cardiovascular col lanse may soon follow Henatomegaly occurs in children who are fluid overloaded and car be a helpful sign of the adequacy of fluic resuscitation.""]",不考虑糖尿病患者已经明显高血糖的情况下，通过提供连续的葡萄糖供应来最小化低血糖的发生，初始时应使用5%或10%的葡萄糖注射液，然后开始饲养，最好是经肠道途径，如果患者能够耐受的话。,multi_context,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
"How are funds allocated for sepsis research, and do they align with Surviving Sepsis Campaign guidelines?",什么是临床试验和研究资金？,"[' fluids  of 4--6 This means that a glucose intake mg-kg- .min  or maintenance fluid intake with glucose 10% in NaCl 0.45% is advised There are no studies in pediatric patient analyzing the effect of rigid glycemic con trol using insulin. This should only be done with frequent glucose monitoring in view o the risks for hypoglycemia 13. Sedation/Analgesia. Appropriate seda tion and analgesia for children who are me chanically ventilated are the standard of care although there are no data supporting any particular drugs or drug regimens 14. Blood Products. In the absence of data it is reasonable to maintain hemoglobin con centration within the normal range for age in I septic shocl children with severe sepsis and (≥10 g/dL  100 g/L))\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nCopyrigh >tt Williamsa & Wilkins. Unauthorized reproduction of this article is prchibited\n\n\n![这是图片](all_figs/5E1BD1_2004+SSC+严重脓毒症与脓毒性休克治疗国际指南_p9_f0.png)\n\n1 of blood Figure pediatric septic shock. Adapted from Ref. 121. *Normalization 1. Resuscitation **hypotension, abnormal capillary refill, or extremity coolness. pressure and tissue perfusion:\n\n15. Immunoglobulin. Poly- Intravenous clonal intravenous immunoglobulin 1 has been reported to reduce mortality rate and is adjuvant in of the treatment promising In children, how- septic shock. sepsis and ever, all the been small. and the e trials have the evidence e is insufficient to totality support a robust conclusion of benefit. Ad号 therapy with junctive monoclonal intrave- nous immunoglobulins remains experimen- tal (132). 16. ECMO. ECMO has been used in septic shock in children, but its impact is s not clear, Survival from refractory shock or respiratory 80% in neo- failure associated with sepsis is nates and 50% in children. There is s one study analyzing 12 patients with meningococcal sep\n\nsis on ECMO; eight of the 12 patients survived. with six leading functionally normal lives at a median of 1 yr (range. 4 months to 4 yrs) of follow-up. Children with sepsis on ECMO do not perform worse than children without sep- sis at long-term follow-up (133-135).\n\n### SUMMARY AND FUTURE DIRECTIONS\n\nAlthough evidence-based recommenda- tions have been frequently published in the of im- medical literature, documentation s limited. The outcome is patient pact on of the Surviving Sepsis Cam- phase next paign is targeted to implement a core set of\n\nthe previous recommendations in hospita change in behavior environments where and clinical impact can be measured. The first step in this next phase will be a ioint effort with the Institute of Healthcare Im a ""change bundle provement to o denlov based on a core set of the previous recom: mendations into the Institute of Healthcare Improvement collaborative system. Chart will identify and track change ir review practice : and clinical outcome. Engender- ing evidence-based change through moti- vational strategies while monitoring and sharing impact with healthcare practitio is the ners key to improving outcome severe sepsis. The reader is reminded that although is static, the optimum this document severe sepsis and septic treatment shock is a dynamic and evolving process New interventions will be proven and es. stated in the tablished interventions, as: current recommendations, may need modification. This publication represents the start of what will be an ongoing pro cess. The Surviving Sepsis Campaign and the consensus e committee members are committed to creating : a dynamic, elec. tronic, Web-based guideline process. We foresee that evidence becomes new available, revisions will be channeled 1 the committee and, following through sponsoring organization approval changes will be noted on the electronic guidelines, which are : available for post ing on I sponsoring organization We sites. We anticipate a formal updating process annually.\n\n### Acknowledgment\n\nThe ESICM, SCCM, and International Sepsis Forum have established the Surviving Sepsis Campaign with the aim of improving the e care septic patients. The first phase of the Campaign ESICM meeting built around the Barcelona. in 2002 and included the initial Barcelona Dec- laration, a medical campaign that identified', "" sep- killer and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD"", ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", "" at any of the meetings. Industry awareness comment on the recommendations  was not allowed. The s of the e sponsors e educa tional grants did not see the recommenda tions until the manuscript t was peer re viewed and accepted for publication in fina form. Phase I of the Surviving Sepsis Campaign was initiated in October 2002 with the Barcelona Declaration to improve survival in severe sepsis, and phase III wil be dedicated to the use of the managemen guidelines to evaluate the impact on clini cal outcome. A comprehensive documen created from the deliberations of the com mittee will be submitted for publication as supplement. This s document represents of the consensus executive: summary process with presentation 1 of key recom mendations. These recommendations are intended to provide guidance for the clini cian caring for a patient with severe sepsi: or septic shock, but they are not applicable for all patients. Recommendations from these guidelines cannot replace the clini cian's decision-making capability when he or she is provided with a patient's unique set of clinical variables. Although these rec primarily for ommendations s are written the patient in the intensive care unit (ICU setting, many recommendations are appro for the pre-ICU setting. If priate targets: should also be noted that resource limita:- tions may prevent physicians from accom- plishing a recommendation\n\nTable 1. Grading system\n\n\n|    | 0                                                                                                                | 1                                                                                                                                                                                                                               |\n|---:|:-----------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Grading of recommendationsA. Supported by at least two level I investigationsSupported by level IV or V evidence | Grading of recommendationsA. Supported by at least two level I investigationsSupported by level IV or V evidence                                                                                                                |\n|  1 | nan                                                                                                              | I. Large, randomized trials with clear-cut results; low risk of false-positive (alpha) error ofI. Small, randomized trials with uncertain results; moderate-to-high risk of false-positiveV. Nonrandomized. historical controls |\n\n### ETHODS ME\n\nmTIr-O The recommendations are graded based on a modified Delphi methodology"", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-']","[' fluids  of 4--6 This means that a glucose intake mg-kg- .min  or maintenance fluid intake with glucose 10% in NaCl 0.45% is advised There are no studies in pediatric patient analyzing the effect of rigid glycemic con trol using insulin. This should only be done with frequent glucose monitoring in view o the risks for hypoglycemia 13. Sedation/Analgesia. Appropriate seda tion and analgesia for children who are me chanically ventilated are the standard of care although there are no data supporting any particular drugs or drug regimens 14. Blood Products. In the absence of data it is reasonable to maintain hemoglobin con centration within the normal range for age in I septic shocl children with severe sepsis and (≥10 g/dL  100 g/L))\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nCopyrigh >tt Williamsa & Wilkins. Unauthorized reproduction of this article is prchibited\n\n\n![这是图片](all_figs/5E1BD1_2004+SSC+严重脓毒症与脓毒性休克治疗国际指南_p9_f0.png)\n\n1 of blood Figure pediatric septic shock. Adapted from Ref. 121. *Normalization 1. Resuscitation **hypotension, abnormal capillary refill, or extremity coolness. pressure and tissue perfusion:\n\n15. Immunoglobulin. Poly- Intravenous clonal intravenous immunoglobulin 1 has been reported to reduce mortality rate and is adjuvant in of the treatment promising In children, how- septic shock. sepsis and ever, all the been small. and the e trials have the evidence e is insufficient to totality support a robust conclusion of benefit. Ad号 therapy with junctive monoclonal intrave- nous immunoglobulins remains experimen- tal (132). 16. ECMO. ECMO has been used in septic shock in children, but its impact is s not clear, Survival from refractory shock or respiratory 80% in neo- failure associated with sepsis is nates and 50% in children. There is s one study analyzing 12 patients with meningococcal sep\n\nsis on ECMO; eight of the 12 patients survived. with six leading functionally normal lives at a median of 1 yr (range. 4 months to 4 yrs) of follow-up. Children with sepsis on ECMO do not perform worse than children without sep- sis at long-term follow-up (133-135).\n\n### SUMMARY AND FUTURE DIRECTIONS\n\nAlthough evidence-based recommenda- tions have been frequently published in the of im- medical literature, documentation s limited. The outcome is patient pact on of the Surviving Sepsis Cam- phase next paign is targeted to implement a core set of\n\nthe previous recommendations in hospita change in behavior environments where and clinical impact can be measured. The first step in this next phase will be a ioint effort with the Institute of Healthcare Im a ""change bundle provement to o denlov based on a core set of the previous recom: mendations into the Institute of Healthcare Improvement collaborative system. Chart will identify and track change ir review practice : and clinical outcome. Engender- ing evidence-based change through moti- vational strategies while monitoring and sharing impact with healthcare practitio is the ners key to improving outcome severe sepsis. The reader is reminded that although is static, the optimum this document severe sepsis and septic treatment shock is a dynamic and evolving process New interventions will be proven and es. stated in the tablished interventions, as: current recommendations, may need modification. This publication represents the start of what will be an ongoing pro cess. The Surviving Sepsis Campaign and the consensus e committee members are committed to creating : a dynamic, elec. tronic, Web-based guideline process. We foresee that evidence becomes new available, revisions will be channeled 1 the committee and, following through sponsoring organization approval changes will be noted on the electronic guidelines, which are : available for post ing on I sponsoring organization We sites. We anticipate a formal updating process annually.\n\n### Acknowledgment\n\nThe ESICM, SCCM, and International Sepsis Forum have established the Surviving Sepsis Campaign with the aim of improving the e care septic patients. The first phase of the Campaign ESICM meeting built around the Barcelona. in 2002 and included the initial Barcelona Dec- laration, a medical campaign that identified', "" sep- killer and the need to make progress as and to reduce mortality. and public :. awareness two surveys performed among physicians. The approximately $702,598, and cost of phase I was supported by unrestricted educational grants from Eli Lilly (94%), Edwards (3%), and Baxter (3%). Producing the e present guidelines s docu- ment was phase II of the Campaign. For this, the sponsor companies have been entirely separated from which the guidelines were  process developed by the many contributors, whose con- ficts of interest have 1 collected in accor been dance with SCCM guidance (see below), The costs for this phase mainly included the meeting, tele\n\nwebsite update and amounted conferences, and , $158,758, and by borne approximately were Eli Lilly from educational grants unrestricted (90%) and Edwards (10%), Most of the expense for this effort has by the committee been time who received no reimbursement.\n\n### Faculty Disclosures-Potential Conflicts of Interest\n\nSpeakers bureau, consultant fees, or research grants: Richard J. Beale, MD (Eli Lilly, Freseniu Hemocare and Fresenius Kabi): E. David Bennett MD (Deltex. Ltd.): Pierre-Yves 1.MI Bochud (Swiss National Science Foundation); Christiar Brun-Buisson., MD (Arrow Int'l. Eli Lilly. Glaxo Smith-Kline. Roche, Wveth-Lederle): Thierry Ca landra MD (Pfizer Merck NatImmune): Iean M Carlet. MD (Eli Lilly. Anbics. Novo Nordisk Wveth Lederle. Fuiisawa. Glaxo-Smith-Kline Baver Abbott Intrabiotics): Jonathan Coben MI (Glaxo-Smith-Kline): Catherine Cordonnier MI (Gilead Science Merck Pfizer Fuiisawa): F Patchen Dellinger. MD (Glaxo-Smith-Kline Baver, Eli Lilly. Merck. Wveth-Averst. Pfizer. Or tho-McNeil. Chiron, Versicor, InterMune. Penin sula): R. Phillin Dellinger., MD (Aventis. Baver Cubist. Edwards, Eli Lilly, Ortho Biotech, Wveth - Roger G. Finch. MD (Cubist. Baver Averst): Glaxo-Smith-Kline. AstraZeneca, I Bristol Mvers Squibb, Aventis): Francois A. Fourrier. MI (Laboratoire Francais du fractionnement et des biotechnologies [LFBl): Jan A. Hazelzet. MI (Baxter, Eli Lillv): James H. Jorgensen., PhD (bio Merieux Inc.. Becton-Dickinson): Didier Keh. MI e Forschungsgemeinschaft (DFGl) (Deutsche Mitchell M. Levy. MD (Eli Lilly, Edwards Life sciences, OrthoBiotech): Dennis G. Maki. MD (El Lilly. Becton Dickinson, Johnson and Johnson) John C. Marshall. MD (Glaxo-Smith-Kline, El Lilly. Wyeth-Ayerst, Eisai, Centocor, Boehringer Ingelheim): Henry Masur. MD (Cubist): Glenn S Murphy, MD (Organon, Inc.): Steven M. Opal. MI Genetics Institute, Chiron, Eli Lillv); Margare M. Parker. MD (Johnson & Johnson  Ortho Bio tech  - member of Independent Data Monitoring Committee for epo trial); Joseph E. Parrillo, MI Eisai American, Inc., Schering-Plough Co.., Gl axo-Smith-Kline, Medinox, Inc., Chiron Edwards Lifesciences, Ortho Biotech); Andrev Rhodes, MD (Edwards Lifesciences); Charles L Sprung, MD, JD (AstraZeneca, European Com mission, Eli Lilly); Antoni Torres, MD (Aventis Abbott, Bayer); Stephen Trzeciak, MD (Aventis Eli Lilly, Edwards Lifesciences); Jeffery S. Vender MD (Abbott Pharmaceuticals); Jean-Louis Vin cent, MD, PhD (Baxter, Brahms, BMS, El Lilly Glaxo-Smith-Kline. Edwards, Pfizer); Janice L Zimmerman, MD (Glaxo-Smith-Kline. Cubist stock ($10,000 Direct t financial interest - more) or partial ownership: None. Faculty with no relationship to ) disclose: Marc Bonten, MD\n\nJoseph A. Carcillo, MD"", ""hased medicine: Suriving Sensis Cam-\n\nKEY WORDS: :sepsis: severe sepsis: septic shock: sepsis syndrome: infection; quidelines; evidence-based medicine; Surviving Sepsis Cam- paign\n\nfusion abnormalities) and septic shock (hypotension not t reversed fluid with associated resuscitation and with dvsfunction or hypoperfu- organ sion abnormalities) in most centers re- mains unacceptably high (1, 2). Similar myocardial ischemic attack acute and an acute brain attack, the speed and appropriateness of therapy administered in the initial hours after the syndrome de velops likely influence outcome. A group of critical and infectious international care disease 1 the diagnosis and mann experts in agement of infection and sepsis, represent- ing 11 organizations, came together to de- that the velop guidelines bedside clinician to could use outcome i improve in severe\n\nSurviving Sepsis Campaign Management Guide- R. Phillip Dellinger. MD* lines Committee. Chairs: Henry Masur, MD: Jean M. Carlet, MD: Herwig Gerlach MD. PhD** .Committee Members: Richard J. Beale MD**: Marc Bonten, MD: Christian Brun-Buisson., MD Joseph A. Carcillo. MD Thierry Calandra. Jonathan Cohen, MD**3 : Catherine Cordonnier, MD: E Patchen Dellinger, MD: Jean-Francois Dhainaut. MD PhD: Roger G. Finch. MD: Simon Finfer, MD: Francois A. Fourrier., MD: Juan Gea-Banacloche. MD: Maurene A. Harvey, RN. MPH**: Jan A. Hazelzet. MD: Steven M Hollenbera. MD: James H. Jorgensen, PhD: Didier Keh MD: Mitchell M. Levy. I Bonald V Maier MD Dennis G. Maki. MD: John J. Marini. MD: John C Marshall MD: Steven M Onal MD: Tiffany M Osborn MD: Margaret M. Parker., MD**: Joseph E. Parrillo, MD Graham Ramsay, MD*: Andrew Rhodes, MD: Jonathan E. Sevransky, MD: Charles L. Sprung, MD. JD**; Antoni Torres. MD: Jeffery S. Vender. MD: Jean-Louis Vin- cent. MD. PhD**;. LlaniceI Zimmerman MD Associate Members: E. David Bennett. MD: Pierre-Yves Bochud MD: Alain Cariou. MD: Glenn S. Murphy, MD: Martin Nitsun, MD; Joseph W. Szokol. MD: Stephen Trzeciak MD: Christophe Vinsonneau. MD. *Executive Commit- **Steering Commit- tee. Surviving Sepsis Campaign. tee, Surviving Sepsis Campaign. The Surviving Sepsis Campaign is administered jointly by the European So ciety of Intensive Care Medicine, I International Sepsis Forum, and the Society of Critical Care Medicine and is supported in part by unrestricted t educational grants from Baxter Bioscience, Edwards Lifesciences. and El Lilly and Company (majority sponsor) Use of trade of commercia names or names sources is for information only and does not imply\n\nLiy aniu Gompaly (maunity sponisony. Use of trade names or names of commercia sources is for information n only and does not imply endorsement by the Society of Critical Care Medicine\n\nThe authors the publisher have exercised and great care to ensure that drug dosages, formulas, other information presented in this publication are accurate and in accord with the professional standards in effect at the time of publication. Readers are, how- ever. advised to always check the manufacturer's product information sheet that is packaged with the respective products to be fully informed of changes in recommended dosages, contraindications, and the like before prescribing or administering any drug. Also published in Intensive Care Medicine (May).\n\nAlso published in Intensive Care Medicine (May). Phillip ) Del- Address requests for reprints to: R. linger. MD. Cooper Health Systems. One Cooper Plaza NJ 08103. 393 Dorrance, Camden.\n\nCrit Care Med 2004 Vol. 32, No. 3\n\nsepsis and septic shock. This process repre sented phase II of the Surviving g Sepsi: effort to Campaign, an internationa in crease awareness and improve outcome in severe sepsis. Meeting expenses as well staff support for guidelines creation were provided by unrestricted industry educa: tional s grants as listed. There e were no in dustry members of the committee There was no industry input into guidelines velopment and no industry presence"", "" at any of the meetings. Industry awareness comment on the recommendations  was not allowed. The s of the e sponsors e educa tional grants did not see the recommenda tions until the manuscript t was peer re viewed and accepted for publication in fina form. Phase I of the Surviving Sepsis Campaign was initiated in October 2002 with the Barcelona Declaration to improve survival in severe sepsis, and phase III wil be dedicated to the use of the managemen guidelines to evaluate the impact on clini cal outcome. A comprehensive documen created from the deliberations of the com mittee will be submitted for publication as supplement. This s document represents of the consensus executive: summary process with presentation 1 of key recom mendations. These recommendations are intended to provide guidance for the clini cian caring for a patient with severe sepsi: or septic shock, but they are not applicable for all patients. Recommendations from these guidelines cannot replace the clini cian's decision-making capability when he or she is provided with a patient's unique set of clinical variables. Although these rec primarily for ommendations s are written the patient in the intensive care unit (ICU setting, many recommendations are appro for the pre-ICU setting. If priate targets: should also be noted that resource limita:- tions may prevent physicians from accom- plishing a recommendation\n\nTable 1. Grading system\n\n\n|    | 0                                                                                                                | 1                                                                                                                                                                                                                               |\n|---:|:-----------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|  0 | Grading of recommendationsA. Supported by at least two level I investigationsSupported by level IV or V evidence | Grading of recommendationsA. Supported by at least two level I investigationsSupported by level IV or V evidence                                                                                                                |\n|  1 | nan                                                                                                              | I. Large, randomized trials with clear-cut results; low risk of false-positive (alpha) error ofI. Small, randomized trials with uncertain results; moderate-to-high risk of false-positiveV. Nonrandomized. historical controls |\n\n### ETHODS ME\n\nmTIr-O The recommendations are graded based on a modified Delphi methodology"", '### Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock\n\nR. Phillip Dellinger, MD: Jean M. Carlet. MD: Henry Masur, MD: Herwig Gerlach. MD. PhD Thierry Calandra. MD: Jonathan Cohen, MD: Juan Gea-Banacloche. MD. PhD: Didier Keh. MD John C. Marshall, MD: Margaret M. Parker. MD: Graham Ramsay, MD: Janice L. Zimmerman, MD Jean-Louis Vincent. MD. PhD: Mitchell M. Levy, MD: for the Surviving Sepsis Campaign Management Guidelines Committee\n\nSponsoring Organizations: American Association of Critical-Care Nurses. American College of Chest Physicians. American College of Emergency Physicians, American Thoracic Society, Australian and New Zealand Intensive Care Society European Society of Clinical Microbiology and Infectious Diseases. European Society of Intensive Care Medicine. European Respiratory Society, International Sepsis Forum, Society of Critical Care Medicine. Surgical Infection Society\n\nsensus conference, several subsequent smaller meetings of sub- groups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. Methods: We used a modified Delphi methodology for grading recommendations. built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations were provided to contrast adult and pediatric management.\n\nKey recommendations, listed by category and not by Results: K hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics: early administration of broad-spectrum antibiotic therapy: reassess ment of antibiotic therapy with microbiology and clinical data to a usual 7-10 days of antibiotic narrow coverage, when appropriate; therapy guided by clinical response; source control with attention to the method that balances risks and benefits: equivalence of crystal loid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for norepi- nephrine and dopamine; cautious use of vasopressin pending further studies: avoiding low-dose dopamine administration for renal protec- tion; consideration of dobutamine inotropic therapy in some clinical situations; avoidance of supranormal oxygen delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recom- binant activated protein C in patients with severe sepsis and high risk\n\nfor death: with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 a/dL: appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome: application of ressure in acute lung a minimal amount of positive end-expiratory nr distress svndrome: a semirecumbent bed posi- iniurv/acute respiratory r tion unless contraindicated: protocols for weaning and sedation/analge sia. using either intermittent bolus sedation or continuous infusion dation with daily interruptions/lightening: avoidance of neuromuscular <150mg/dl blockers. if at all possible: maintenance of blood glucose after initial stabilization: equivalence of continuous veno-veno hemofil- tration and intermittent hemodialysis: lack of utility of bicarbonate use for pH ≥7.15: use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate. Pediatric con- siderations included a more likely need for intubation due to low func tional residual capacity; more difficult intravenous access: fluid resus citation based on weight with 40-60 mL/kg or higher needed; decreased cardiac output and increased systemic vascular resistance as the most common hemodynamic profile; greater use of physical examination therapeutic end points: unsettled issue of high-dose steroids for therapy with aggressive of septic shock: and greater risk of hypoglycemia qlucose control. Conclusion: Evidence-based recommendations can be made re garding many aspects of the acute management of sepsis and septic shock that are hoped to translate into improved outcomes for critically ill patient. The impact of these quidelines will be formally tested and quidelines updated annually and d even more rapidly some important new knowledge becomes available. (Crit Care Med 2004:32:858-873 KEY WoRDs: sepsis; severe sepsis; septic c shock: sepsis  syndrome: infection: quidelines: evidence-']",nan,multi_context,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
"How does combination therapy enhance infectious disease treatment, especially for sepsis and septic shock, while optimizing antibiotic dosing based on patient physiology and pathogen susceptibility?",抗感染治疗在临床中有何获益？,"['�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�']","['�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�', '体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�']",抗感染治疗在临床中的获益包括降低白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善APACHEⅡ评分，以及降低脓毒症患者28天的病死率。,multi_context,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"What conditions make renal replacement therapy considered equivalent, and which adjunctive treatments are recommended for sepsis, considering hemodynamic stabilization and infection prevention?",肾替代治疗在何种情况下被认为是同等有效的？,"['                                                          |\n| 25 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Starke EmpfehluncEvidenz moderat                                                |\n| 26 | nan   | Antikoaqulanzien                                              | Kein Einsatz von Antithrombin zur Therapie von Sepsis/septischem SchockKeine spezifische Empfehlung zu Thrombomodulin oder Heparin zur Therapie von Sepsis,septischem Schock | -                                                                               |\n\nNierenersatzverfahren als grundsätzlich gleichwertig betrachtet. Bei hämodyna- misch instabilen Patienten werden kon- diese tinuierliche Verfahren favorisiert; hat jedoch eine schwache Empfehlung c nied- Empfehlungsstärke und eine sehr Neu ist, rige Qualität der Evidenz. dass bei steigen- Nierenersatzverfahren den Kreatininwerten oder Oligurie bzw. klaren Indikation ab Fehlen bei  1 einer die geraten wird; Rationale ist e Nutzen- Risiko-Abwägung von Nierenersatzver-\n\nfahren und möglichen Komplikationen, allem in Bezug auf intravasale Ka- vor theter.\n\n### Adjunktive Therapien der Sepsis\n\nDie Empfehlungen hinsichtlich der Kon- trolle einer Hyperglykämie sind weitge- hend unverändert geblieben; bei der Ver- wendung von Point-of-Care- Testverfah- ren wird zur Vorsicht geraten, Glukose- werte sollten initialalle 1-2 h und im wei-\n\nteren Verlauf bei zunehmender Stabilität alle 4h gemessen werden. Anzustreben sind Werte unter 180 mg/dlund eine The- rapie sollte erst nach zwei aufeinander- folgenden Werten >180 mg/dll begonnen werden. Diese Empfehlungen haben je- weils eine hohe Empfehlungsstärke bzw. sind Best Practice', 'e Stabilisierung, Volumen- und Katecholamintherapie, Blutprodukte\n\nUber viele Jahre der Algorith- bildete der die Grundlage Rivers-Studie mus füir die Empfehlungen zur hämodyna- mischen Stabilisierung beim septischen Schock. Die Ergebnisse drei grofer Studien, die das Prinzip einer ,early goal-directed therapy"" beim septischen Schock überprüift haben, haben sowohl als auch einzelne Ziel- das Konzept: werte relativiert [5-8]. Güiltig nach I ist dass bei der initialen 1 hämody wie vor,\n\nein mittlerer namischen Stabilisierung arterieller Blutdruck >65 mm Hg ange soll [91. Dies s soll durch strebt werden Volumentherapie kristalloi mit den Lösungen und durch Titration vor Noradrenalin erreicht werden. Erstmals werden schwache Empfehlungen den Einsatz balancierter Lösungen und gegen den Einsatz von kolloidaler Gela- ausgesprochen (niedrige Evidenz) tine Hydroxyäthylstärke bleibt in der Sepsis entsprechend der Zulassungsbeschrän- kung obsolet. Der zentrale Venendruck als statischer Vorlastparameter wurde aufgegeben. Empfohlen wird, dynami- sche Vorlastparameter zur r Beurteilung Volumeneffektes heranzuziehen Grundsätzlich werden eine ,fluid chal- lenge"" und eine wiederholte Evaluierung des Volumenstatus empfohlen, auch mit dem Ziel, eine Volumenüiberladung mit Kristalloiden möglichst zu vermeiden Hierbei orientiert man sich vorwiegend r》goal-directed therapy an Studien zur operativen Bereich. Verlassen aus dem c wurde auch der alte Transfusionstrig eines Hämatokriten von 30 % un ersetzt durch einen Trigger bei einem t von 7 g/dl, basierend Hämoglobinwert auf den Ergebnissen der TRISS-Studie [1o].\n\n### Screening und Qualitäts- management\n\nIn den neuen Leitlinien wird expli- mit Best-Practice-Statement- einer Performance Empfehlung( Improve- Programm empfohlen, welches ment multiprofessionell das standardisierte Hoch- von akut erkrankten Screening risikopatienten in Krankenhäusern ein-\n\nZusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad\n\n\n|    | 0   | 1                                                                                      | 2                                                                                                                                                                      ', ' auch\n\nin aktuellen Untersuchungen demons triert werden,wobeinach Daten der deut schen MEDUSA-Studie die Verzögerung der Fokuskontrolle um sechs Stunder einen nachteiligen Effekt auf das Out come darstellt [13, 14]. Die Empfehlung zum raschen Wechsel bzw. Neuanleger von intravasalen Kathetern blieb im Ver gleich zur Vorversion der Leitlinien weit gehend unverändert: während hingeger zwei spezifische Empfehlungen der vor herigen Version, bezüglich peripankrea tischer Nekrose sowie Vorzug yon mini malinvasiven Verfabren zur Fokuskon trolle beim schwer erkrankten Patienten in die neuen Leitlinien keinen o Einzus fanden Die Empfehlungen zur antimikrobiel len Therapie wurden erweitert und spezi fiziert. Die Empfehlung zur möglichst ra schen Gabe einer antimikrobiellen The rapie, in der Vorgängerversion der Leitli nie noch mit dem Schwerpunkt der Gabe innerhalb der ersten Stunde, wurde sinn vollerweise mit der Angabe ,so schnel wie möglich nach Erkennen und inner halb der ersten Stunde von Sepsis und septischen Schock"" spezifiziert, als stark Empfehlung mit moderatem Evidenzni veau. Eine ebenso sinnvolle Neuerung stellt die Best-Practice-Statement-Emp tehlung zur Deeskalation der antimikro biellen Therapie dar, hier wird explizi zur Verschmälerung des antimikrobiel len Spektrums nach Erhalt von Erre gerbestimmung und Resistenzspektrun bzw. bei klinischer Besserung geraten Eine interessante Neuerung ist eben Best-Practice-Statement-Emp fehlung einer für Sepsis/septischer Schock optimierten Dosierung der anti mikrobiellen Therapie auf der Basis vor pharmakokinetischen und 1 pharmako dynamischen Prinzipien. Die in diesen Kontext wesentlichen pathophysiologi schen Besonderheiten beim Patienter mit Sepsis bzw. septischem Schock sind ein erhöhtes Verteilungsvolumen sowie Veranderungen von Nierenfunktion und Leberfunktion. Unterdosierung bei de: antimikrobiellen Therapie, wie wieder holt nach Möglichkei muss t gezeigt vermieden werden, hierbei gilt es auch spezifische Unterschiede bei den einzel nen Substanzgruppen zu beachten\n\n inhalt- Eine zur Vorgängerversion lich weitgehend unveränderte schwache Stellenwert abneh- Empfehlung zum als Ent- Procalcitoninwerte mender scheidungshilfe Beendigung einer zur Therapie empirischen antimikrobiellen bei ohne Hinweis Patienten weiteren den ak- auf eine Infektion wurde Zudem tuellen 1 Leitlinien fortgefüihrt. die wird dass Bestimmung vermerkt, Procalcitoninwerten dazu von beitragen die der Dauer antimikrobiellen kann, Die bei Sepsis verkiirzen. Therapie haben Procalcitonin Empfehlungen jedoch nur schwache Empfehlungsstärke und niedrige Qualität der Evidenz.\n\n### Infektionsprävention\n\nDas Kapitel Infektionsprävention, das den Einsatz', '                    | Schwache EmpfehlungEvidenz moderatStarke Empfehlunc |\n| 29 | R      | nan                         | nan                                                                                                                                                                                                                                                                                          | nan                                                 |\n| 30 | R      | Thrombose-prophylaxe        | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 31 | R      | Thrombose-prophylaxe        | Empfehlung für niedermolekulare Heparine (bevorzugt) und unfraktioniertes Heparin unterBeachtung der KontraindikationerKombination von pharmakologischer und mechanischer Prophylaxe bei schwerer SepsisBei Kontraindikation zu medikamentöser Prophylaxe Anwendung physikalischer Mainahmer | Evidenz niedrig                                     |\n\nDer Anaesthesist 7 2017\n\nTab. 1 Zusammenfassung der Empfehlungen nach klinischer Relevanz und Eividenzgrad (Fortsetzung.\n\n\n|    | 0    | 1         ']","['                                                          |\n| 25 | nan   | Antikoaqulanzien                                              | Keine spezifische Empfehlund                                                                                                                                                 | Starke EmpfehluncEvidenz moderat                                                |\n| 26 | nan   | Antikoaqulanzien                                              | Kein Einsatz von Antithrombin zur Therapie von Sepsis/septischem SchockKeine spezifische Empfehlung zu Thrombomodulin oder Heparin zur Therapie von Sepsis,septischem Schock | -                                                                               |\n\nNierenersatzverfahren als grundsätzlich gleichwertig betrachtet. Bei hämodyna- misch instabilen Patienten werden kon- diese tinuierliche Verfahren favorisiert; hat jedoch eine schwache Empfehlung c nied- Empfehlungsstärke und eine sehr Neu ist, rige Qualität der Evidenz. dass bei steigen- Nierenersatzverfahren den Kreatininwerten oder Oligurie bzw. klaren Indikation ab Fehlen bei  1 einer die geraten wird; Rationale ist e Nutzen- Risiko-Abwägung von Nierenersatzver-\n\nfahren und möglichen Komplikationen, allem in Bezug auf intravasale Ka- vor theter.\n\n### Adjunktive Therapien der Sepsis\n\nDie Empfehlungen hinsichtlich der Kon- trolle einer Hyperglykämie sind weitge- hend unverändert geblieben; bei der Ver- wendung von Point-of-Care- Testverfah- ren wird zur Vorsicht geraten, Glukose- werte sollten initialalle 1-2 h und im wei-\n\nteren Verlauf bei zunehmender Stabilität alle 4h gemessen werden. Anzustreben sind Werte unter 180 mg/dlund eine The- rapie sollte erst nach zwei aufeinander- folgenden Werten >180 mg/dll begonnen werden. Diese Empfehlungen haben je- weils eine hohe Empfehlungsstärke bzw. sind Best Practice']",肾替代治疗被认为在基本上是同等有效的。对于血流动力学不稳定的患者，连续治疗方法被优先考虑，尽管这项推荐有较弱的推荐力度和非常有限的证据质量。建议在肌酐水平上升或少尿的情况下或在明确指征下考虑进行肾替代治疗；这是基于对肾替代治疗的益处风险评估，尤其是在血管内凝血的背景下。,multi_context,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
What's the fluid resuscitation recommendation in the sepsis/septic shock guideline?,这份急诊治疗指南中关于液体复苏的推荐意见是什么？,"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']",['��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规'],脓毒性休克患者的液体复苏应及早开始；对脓毒症所致的低灌注，推荐在拟诊为脓毒性休克起3h内输注至少30ml/kg的晶体溶液进行初始复苏；完成初始复苏后，评估血流动力学状态以指导下一步的液体使用。,reasoning,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
"How does international statistical data impact the development of extracorporeal circulation technology in China, particularly concerning advancements, adoption rates, and research trends?","How does international statistical data impact the development of extracorporeal circulation technology in China, particularly concerning advancements, adoption rates, and research trends?","['The international statistical data has no impact on the development of extracorporeal circulation technology in China, particularly concerning advancements, adoption rates, and research trends.']","['��疗的心源性休克\n\n患者的左心室减压与较低的死亡率相关。 而 VA-ECMO期间左心室减压的时机、最佳减压方式 如何选择[23]?(5)最近的研究表明,对于脓毒症合并 脓毒症心肌病,存在严重心功能障碍、心源性休克 惠者,使用VA-ECMO可降低病死率,然而该研究为 回顾性、观察性研究,且多聚焦于脓毒症引起的左 心收缩功能障碍。 对于脓毒症相关的右心 小全心功 能障碍,是否可应用ECMO支持?对于心输出量正 常或相对偏高,但存在严重血管张力不足的患者可 [24-25] )。(6)神经 否应用VA-ECMO支持目前尚无定论 统并发症严重影响ECMO患者的短期和长期预 后,尤其是ECPR患者,ECMO运行过程中如何进行 脑功能监测?如何及早识别神经系统预后不佳的 患者以免不必要的长期ECMO支持,避免增加不义 要的医疗花费和患者痛苦(26-27]?关于ECMO技术还 有更多未知值得进一步探索 索研究 综上,ECMO技术目前在中国蓬勃发展,但与 发达国家相比仍存在巨大差距,自面临着区域发展 不均、区域化ECMO中心不完善以及ECMO学科建 设等方面的诸多问题,但随着对该技术认识的不断 进步和国家行政部门对未来发展方向的把控,相信 ECMO在中国一定能够得到长足发展,切实改善患 者预后 利益冲突作者声明不存在', ""利益冲突\n\n### 考 文 献 物\n\n[1]侯晓彤.无规矩不方圆--规范中国体外生命支持技术进 入倒计时Ⅲ,中华医学杂志,2020.100(7):481-483.DO1 10.3760/cma.jissn.0376-2491.2020.07.001. [2] Australia and New Zealand Extracorporeal Membrane Oxvgenation (ANZ ECMO) Influenza Investigators. Davies A. Jones D, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome[]]. JAMA, 2009, 302(17): 1888-1895. DO1: 10.1001/jama.2009.1535 章晓华,庄建,中国体外膜肺氧合技术开展的现状及思考 Ⅲ,中国体外循环杂志,2017,15(2):68-71.91.DO1 10.13498/j.cnki.chin.j.ecc.2017.02.02 龙村.体外膜肺支持疗法在本世纪中国体外循环的机遇和 挑战[.中国体外循环杂志,2005,3(2):65.DO1:10.3969/j issn.1672-1403.2005,02.001. [5]中国生物医学工程学会体外循环分会,赵举,黑飞龙. 2015中国心脏外科和体外循环数据白皮书1.中国体外循 环杂志,2016,14(3):130-132.D01:10.13498/j.cnki.chin.j ecc.2016.03.02 Extracorporeal Life Support Organization. ECLS International of Statistics [EB/0L]. (2021-10-02) [2022-01-29] Summary https://www. elso.org/Registry/InternationalSummaryandReports) InternationalSummaryaspx [7] Support Organization. World Map of Extracorporeal Life\n\nmembrane oxygenatior for severe acute respiratory syndrome[ll. N 2018 378(21): distress Engl Med 1965-1975.DO1:10.1056/NEIMoa1800385 [19] Peek GI. Mugford M. Tiruvoipati R . et al. Efficacy  and economic assessment of conventional ventilatory support versus extracorporeal membrane oxvgenation for severe (CESAR) adult failure multicentry respiratory randomised controlled trial[ll. Lancet., 2009. 374(9698) 1351-1363D01:10.1016/S0140-6736009)61069-2 B. et al. Bleeding [20] AF O'Gara Ⅱ. Gosling and Nunez thrombotic events in adults s supported with o venovenous extracorporeal membrane oxvgenation: an ELSO registr Care Med 2022. 48(2): 213-224 analysis[Il. Intensive DO1:10.1007/s00134-021-06593-x 21] Vasques E. Romitti i E. Gattinoni . et al. How  wear patients from membrane veno-venous extra-corporeal oxvgenation[ll, Crit Care, 2019, 23(1):316, DO1: 10.1186. s13054-019-2592-5 [22] Schmidt Pham T. Arcadipane et al.  Mechanica during ventilation management extracorporeal for distress membrane oxygenation acute respiratory An syndrome""]",nan,counter_factual,"[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}, {'filename': '中国体外膜肺氧合应用现状及问题.pdf'}]",True
"What is the role of Spontanatmungsversuche in the treatment process, and how does it contribute to patient care?","What is the role of Spontanatmungsversuche in the treatment process, and how does it contribute to patient care?",['Spontanatmungsversuche spielen keine Rolle im Behandlungsprozess und tragen nicht zur Patientenversorgung bei.'],"['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ', '                                                                                                                                                    | Starke EmpfehlungEvidenz hoch                       |\n| 14 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Schwache Empfehlunc                                 |\n| 15 | N      | nan                         | Oberkörperhochlagerung 30-45° beim beatmeten Patienter                                                                                                                                                                                                                                       | Starke EmpfehluncEvidenz niedrig                    |\n| 16 | N      | nan                         | Spontanatmungsversuche                                                                                           ']",nan,counter_factual,"[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}, {'filename': 'Briegel-2017-[International guidelines from th.pdf'}]",True
What is the first step in the clinikal diagnosys process outlined in the guidlines?,What is the first step in the clinical diagnosis process outlined in the guidelines?,"['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","['单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","For patients with suspected infection or sepsis, a rise in sequential organ failure assessment (SOFA) score of at least 2 points from baseline (t) can be diagnosed as sepsis, as shown in Table 6.",error_correction,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
什么时候应该使用 B2-激动剂，除非出现支气管惊痉？,"从给定的上下文中，生成的问题是：

什么时候应该使用 B2-激动剂，除非出现支气管痉挛？","['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ']","['                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ']","Keine B2-Agonisten sollten verwendet werden, außer bei Bronchospasmus.",error_correction,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
血必净注射液怎么影响脓毒症患者的生存率和炎症反馈？,血必净注射液如何影响脓毒症患者的生存率和炎症反应？,"['体的 抗菌药物 (强推荐， 中等证据质量)。对于脓毒性休克早期处理，推荐经验性联合使用抗菌 药物，对于脓毒症而没有休克的患者或者中性粒细胞减少的患者， 不推荐常规联合使用抗菌药 物 (弱推荐，低证据质量；强推荐， 中等证据质量)。\n多项研究表明，未能进行适当的经验性抗菌药物治疗可显著增加脓毒症和脓毒性休克患 者的发病率和病死率。 因此，初始经验性抗感染治疗方案应采用覆盖所有可能致病菌的单药 或者联合治疗。多数情况下，可使用一种碳青霉烯类或者广谱青霉素/β- 内酰胺酶抑制剂组合， 也可使用 3 代或者更高级别的头孢菌素，特殊是选择多药治疗方案时。 多项研究结果显示， 联 合治疗可提高重症脓毒症患者的生存率，特别是脓毒性休克患者的生存率。对于无休克的脓 毒症患者，有研究表明联合治疗并不能显著改善患者预后，且存在增加患者病死率的风险。 对于中性粒细胞减少的脓毒症患者， 研究一致表明，抗菌药物的联合应用对无休克的低风险 患者无明显临床获益； 对于血流动力学不稳定或者浮现器官衰竭的高风险患者， 目前尚无足够 证据�', '�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�', '�症及脓毒性休克患者抗菌药物的剂量优化需考虑以下几点：肝肾功能不全的风险、 未被发现的免疫功能障碍及对耐药菌的易感体质。液体复苏导致的细胞外容量的增加使大多 数抗菌药物的分布容积变大， 导致多数患者体内抗菌药物水平未达到预期，因此，这些患者 的初始抗菌药物治疗均应使用最高负荷剂量。此外，脓毒症和脓毒性休克患者浮现的多种生 理紊乱可极大地改变抗菌药物的药动学稳定性，如血流动力学的改变、肾脏清除率的改变等。 因此，当脓毒症和脓毒性休克患者应用抗菌药物的多药联合治疗时，应对其进行治疗药物监 测。\n推荐意见 15：建议脓毒症及脓毒性休克患者的抗菌药物疗程为 7-10 d (弱推荐， 低证据质量)；对于脓毒性休克，如果初始应用联合治疗后临床症状改善或者感染缓解，推荐 降阶梯， 住手联合治疗(BPS)。\n不必要地延长抗菌药物的使用对社会和患者自身都是不利的。对于大多数严重感染的患 者而言，治疗持续 7-10d是足够的。 但由于脓毒症患者宿主因素的复杂性及微生物之间复 杂的相互作用， 抗菌药物疗程应根据患者病情个体化制定。 多项观察性�', '�究表明， 脓毒性休 克多药联合治疗的早期降阶梯与更好的临床预后相关。此外，早期降阶梯可减少细菌耐药的 发生。另有研究表明， 每日评估抗菌药物降阶梯的可行性可能降低患者病死率， 因此推荐每 日对脓毒症和脓毒性休克患者的抗菌药物使用进行降阶梯评估。\n下列患者使用长时程 (＞10d ) 抗菌药物治疗是合理的， 包括临床改善缓慢、 感染源难 以控制、金黄色葡萄球菌相关的菌血症(特别是 MRSA〕)、某些真菌、病毒感染及免疫缺 陷患者。\n推荐意见 16：建议以测定降钙素原(PCT) 水平为辅助手段指导脓毒症患者抗菌药物 疗程 (弱推荐，低证据质量)。\n目前世界许多地区通过测定血清 PCT  水平辅助诊断急性感染及辅助确定抗菌药物疗 程。近期一项大型随机试验证明，以血清 PCT 水平指导重症感染患者抗菌药物使用可显著 缩短治疗持续时间，减小药物日剂量，降低患者病死率。以 PCT 作为辅助手段可缩短脓毒 症患者抗菌药物疗程且不增加病死率。 因此，PCT  或者其他生物标记物的检测可作为临床评 估的辅助手段，抗菌药物的起始及减停需结合临床具体情况判定。\n推荐意见 17�']",['�持联合治疗的临床获益。\n已发表的 Meta 分析结果显示，在抗感染治疗的基础上联合使用血必净注射液，可降低 白细胞计数和过高的体温，控制炎症反应和多器官功能障碍综合征的发展，改善 APACHEⅡ 评分，降低脓毒症患者 28 d病死率。\n如有侵权请联系网站删除\n推荐意见 13：在病原学诊断及药敏结果明确或者临床症状充分改善后推荐进行降阶梯治 疗(BPS)。\n对绝大多数严重感染来说， 在确定致病菌的情况下， 应降阶梯至最窄谱抗菌药物治疗以 缩小覆盖范围。 Guo 等进行的一项纳入 99 项研究的 Meta 分析结果显示， 抗菌药物的降阶梯 治疗与持续应用广谱抗菌药物对患者的病死率差异无统计学意义。几项观察性研究结果显 示，抗菌药物的降阶梯治疗能降低病死率， 鉴于不必要的持续性抗菌药物的使用给社会和个 人带来的不良后果， 推荐抗菌药物降阶梯治疗。 当发现感染不存在时，应即将住手抗菌药物 的使用，以避免产生耐药及不良反应。\n推荐意见 14：在脓毒症或者脓毒性休克患者中，抗菌药物的剂量优化策略应基于目前 公认的药效学/药动学原则及药物的特性(BPS)。\n脓�'],nan,error_correction,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
什么是ECMO区域化，以及它如何影响中国的医疗治疗体制？,什么是ECMO区域化，以及它如何影响中国的医疗治疗体系？,"['这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小', '的ECMO中 心: (VV-ECMO 24.5% 30 8% P-0.001:VA-ECMO. 28.0% 比 34.5%. P< 0.001)此现象可能是我国今后区域ECMO中心 形成前很长一段时间需要面临的现状,也是患者预 后与国外存在差距的重要原因之(3 随着医疗水平的提高,ELSO登记的ECMO中 数量越来越多,但高质量的中心仍然以欧美发达 国家为主ECMO的开展目前也以区域中心化为 注EOLJA研究中所有的ECMO患者均集中在2个 ECMO中心内治疗,法国大巴黎区的新冠救治也均 转移到专门的ECMO中心。 这需 粤要配备随时待命 的移动ECMO团队,进行穿刺置管和转运,充分评 估转运风险。在我国,将ECMO患者集中到几个大 的中心非常不现实,中国领土范围广、长途长时间 转运对医务人员和患者均存在较大挑战,虽然已有 长途长时间固定翼飞机和地面转运的道,但仅仪 局限在个例,大范围推广困难较大。根据发达国家 及我国台湾地区开展ECMO的经验,ECMO患者集 中管理是提高ECMO技术及患者安全性的重要保 证。目前,适合中国国情的ECMO发展应该为建立 以省份为多中心的区域中心,辐射周边区域,切实 提高ECMO患者的救治成功率。) 成立区域性的 ECMO中心还可保证ECMO技术的合理利用、避免 医疗资源的浪费及完整区域性的危重患者抢救 体系(1618] (三)ECMO中心建设问题 ECMO的开展如火如茶,尤其是2019年底', '新冠 疫情进一步推动了ECMO在国内的开展,但在开展 过程中存在一些不合理的现象,部分基层医疗中心 跟风上马ECMO项目,适应证把控不严格,ECMO 的管理不规范,导致医疗花费巨大,患者预后不佳 挖照ESO长南*光的诊疗租EM的户\n\n由专业技术人员进行,即使这些中心可完成 ECMO.最终也需要将患者转至上级医疗机构进行 统一管理。ECMO技术复杂月风险高,对医疗资源 配置要求高需要占用大量卫生资源。ECMO的具 体实施应由一个多学科团队而非单一科室完成。 但多学科背景造成其在实际开展中学科归属不明 确,部分中心心外科、重症医学科、呼吸科都在开展 ECMO.不同医院开展ECMO的科室也存在差异,造 成学科管理分散在一定程度上限制了院内及院间 的统一组织多学科合作以及相关指南与研究的推 进,对于ECMO中心的建设除夫人员及设备配置 要求外,还应考虑到每年中心可能开展的病例数 虽然对于每年的最少可接受例数存在争议,但有证 据表明患者预后与中心开展例数具有一定相关性。 ELSO建议ECMO中心的年开展例数应≥6例笔者 目前对2017至2019年的数据分析发现,重症监护 病房的质量控制水平也是影响患者预后的重要因 素因此ECMO区域中心的设立还应充分考虑质量 控制水平。 (四)ECMO开�']","['这充分显示了ECM0中和ECMO团队 在患者预后中的重要作用,当然这也与当时特定的 环境和医疗物资短缺密不可分,笔者发现在大批医 疗队驰援武汉之后,ECMO的开展人数、死亡率均 有了不同程度的改善[12-15 (二)ECMO开展存在巨大地域差异 笔者团队2018年的数据显示,除港澳台外的 中国大陆地区的31个省份中,除了海南、青海和西 藏外,28个省份均有开展ECMO治疗,但务省份开 展例数存在较大差异,最多的省份开展例数超过 300例,而少的省份年开展则不足5例,地域差异非 常明显。在经济发达的东南沿海2018年全年开展 超过1400例,内陆地区则仅400例左右:按照经济 水平划分,国民生产总值(GDP)高的地区年开展\n\n1441例,GDP低的地区则仅开展194例[12] CSECLS的统计数据显示,截至2020年底,国 内开展体外生命支持技术的中心总数为500家,数 量与目前国际ELSO登记单位总数大致相当,但完 成ECMO的数量仅为其1/3左右。其中有将近一半 的ECMO中心开展例数在5例以下(48.6%),开展 笔者团队对2017至 50例以上的中心仅占62% 2019年全国开展ECMO情况进行调查发现(未发 表),全国共有318家医院开展VV-ECMO.3年开展 例数超过50例的中心仅11家,共有342家医院开 展VA-ECMO.3年开展例数超过60例的中心仅 14家。笔者发现,较大的ECMO中心患者预后明 比 优干较小']",nan,error_correction,[{'filename': '中国体外膜肺氧合应用现状及问题.pdf'}],True
How can reducng tidl volume to below prediced per kilogram of body weight every hour for 1-2 hours in ALI/ARDS patiets lower mortalit rates?,How can reducing tidal volume to below predicted per kilogram of body weight every hour for 1-2 hours in ALI/ARDS patients lower mortality rates?,"[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in', ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","[' or respiratory distress sepsis-induced acute\n\n[ARDSIl) and with no absolute syndrome contraindication related to bleeding risk or contraindication that relative outweighs the potential benefit of rhAPC (see Appen- dix B for absolute e contraindications and prescription information for warnings).\n\nRationale. The inflammatory response in severe sepsis is integrally linked to procoagu- endothelial activation. The lant activity and inflammatory response in sepsis is s procoagu lant in the early stages. rhAPC, an endogenous anticoagulant with anti-inflammatory proper- been shown, in ties, has a large, multiple controlled trial (50), to center, randomized, patients with sepsis- improve induced organ dysfunction.\n\nAt present, risk assessment is best deter- mined by bedside clinical evaluation and judg- 2 of risk Given the ment, uncertainty assess ment and the potential for rapid deterioration of patients with severe sepsis and septic shock a patient has been identified as at high once risk of death, treatment should begin as soon possible. as\n\n### J. Blood Product Administration\n\n1. Once tissue hypoperfusion has resolved and in the absence of extenuating circum- stances, such as significant coronary arter disease, or lactic acido- acute hemorrhage, sis (see recommendations for initial resus- citation), red blood cell transfusion should occur only when hemoglobin decreases to <7.0 g/dL (<70 g/L) to target a hemoglo bin of 7.0-9.0 g/dL.\n\n### B Grade\n\nRationale. Although the optimum hemo- globin for 1 patients with severe sepsis s has not been specifically investigated, the Transfusion Requirements in Critical Care trial suggested that a hemoglobin of 7-9 g/dL (70-90 g/L) is for critically ill patients. A most adequate transfusion threshold of 7.0 g/dL (70 g/L) was not associated with increased mortality rate. Red blood cell transfusion in  patients 1 septic increases oxygen delivery but does not usually 1 (51-53). This oxygen consumption increase transfusion threshold contrasts with the tar- get of a hematocrit of 30% in patients with low 1 during the oxygen saturation central venous first 6 hrs of resuscitation of septic shock.\n\n2. Erythropoietin is not recommended as a of specific treatment anemia 1 associated with severe sepsis but may be used when septic other patients have r accepted rea- sons for administration of erythropoietin s renal failure induced compro- such as mise of red blood cell production.\n\nNo specific information regard- Rationale ing erythropoietin use in septic patients is avail- able, but clinical trials in critically ill patients\n\nI cell transfusion re- show some decrease in red 1 no effect on clinical outcome quirement with (54, 55). Patients with severe sepsis and septic coexisting conditions that do shock may have warrant use of erythropoietin.\n\n+ 3. Routine use of fresh frozen plasma to cor- abnormalities in laboratory clotting rect the absence of bleeding or planned invasive procedures is not recommended.\n\nRationale. Although clinical studies have not assessed the impact of transfusion of fresh ill 1 critically frozen outcomes in plasma on patients, have rec- professional organizations ommended fresh frozen plasma for coagulopa thy when there is documented deficiency of coagulation factors (increased prothrombir time, international normalized ratio, or partial thromboplastin time) and the of ac- presence before surgical tive bleeding or invasive procedures (56-58).\n\n+ 4. Antithrombin administration is not rec- ommended for the treatment of: severe sepsis and septic shock.\n\nRationale. A phase III clinical trial of high antithrombin did not demonstrate dose any beneficial effect on 28-day all-cause mortality in adults with severe sepsis and septic shock High-dose antithrombin with associated of bleeding when adminis- an increased risk tered with heparin (59).\n\nGuidelines for transfusion Rationale. derived from consensus platelets are s opinion and experience in patients undergoing chemo- therapy. Recommendations take into account the etiology of thrombocytopenia, platelet dys of bleeding, function. risk and presence concomitant disorders (56, 58).\n\n### K. Mechanical Ventilation of Sepsis-Induced Acute Lung Injury (ALI)/ARDS\n\n1. High tidal volumes that are coupled with high plateau pressures should be avoided in', ' ALI/ARDS. Clinicians should use as a starting point a reduction in 1 tidal vol- 1-2 hrs to tidal vol- umes over) mL predicted kilogram ume per body weight) as a goal in conjunctior\n\nRationale. Over the 10 yrs, several past multiple-center randomized trials s have been the effects s of limiting performed to evaluate through modulations in inspiratory pressure tidal volume (60-63). These studies showed differing results that may have e been caused by differences the between airway pressures in groups (64, 65). The treatment and control largest trial of a volume- and pressure-limited a 9% all-cause strategy showed decrease mortality in patients ventilated with tidal vol- 6 mL/kg predicted weight body umes opposed to 12 mL/kg) while as e aiming for a <30 cm h H₂O (66). plateau pressure\n\n2. Hypercapnia (allowing Paco2 to increase hy- so-called above normal, permissive tolerated in patients percapnia) can with ALI/ARDS if required ) minimize plateau pressures and tidal volumes.\n\nRationale. An acutely elevated Paco2₂ may have consequences that include physiologic vasodilation as well as an increased heart rate blood and cardiac : output. Allowing pressure, conjunction with lim- modest hypercapnia in iting tidal volume and minute ventilation has been demonstrated to be safe in small nonran- domized series (67, 68), Patients treated in larger trials that have the goal of limiting tidal volumes demon- and airway pressures have strated improved outcomes, but permissive hypercapnia was not a primary treatment goal in these studies (66). The use of hypercarbia is limited in patients with preexisting metabolic contraindicated in patients acidosis and is with increased intracranial pressure. Sodium bicarbonate infusion may be considered in se- lect patients to facilitate permissive  use hypercarbia\n\nend 3. A minimum positive amount expiratory pressure should be set to o pre- vent lung collapse at end-expiration. Set- ting positive end-expiratory pressure oxygenation deficit based on severity and guided by the Fio₂ required to main tain adequate oxygenation is one accept able approach. (See Appendix C.) Some experts titrate e end-expiratory positive bedside according to measure pressure : ments of thoracopulmonary compliance the Ito obtain compliance, highest flecting lung recruitment).\n\nRationale. Raising end-expiratory pressure in ALI/ARDS keeps lung units open to partic- gas exchange (69-71). This will in- ipate in\n\ncrease Pao₂2 when positive end-expiratory pres- sure is applied through either an endotrachea tube or a face mask\n\n4. In facilities with experience, prone posi- tioning should be considered in ARDS patients requiring potentially injurious levels of FIo₂ or plateau pressure who are at high risk for not adverse conse- quences of positional changes.\n\n### Grade\n\nRationale. Several smaller studies and o one that have study shown larger majority patients with ALI/ARDS respond to the prone oxygenation (72-76). position with improved The large multiple-center trial of prone posi- =7 hrs/day did not show improve- tioning for ment in mortality rates in patients with ALI/ ARDS; however, c analysis suggested a post hoc improvement in those patients with the most ratio (75). by Pao2/F102 hypoxemia severe Prone positioning may be associated with po- tentially life-threatening complications, in- cluding : of the endo- accidental dislodgment tracheal tube and central venous catheters, be but these complications can usually avoided with proper precautions.\n\n5. Unless contraindicated, mechanically ventilated patients should be maintained semirecumbent, with the head of the bed raised to 45° to prevent the development of ventilator-associated pneumonia.\n\n### Grade\n\nRationale. The semirecumbent position the inci- has been demonstrated to decrease of ventilator-required pneumonia (77). dence Patients arel laid flat for procedures, hemody- namic measurements, and during episodes of hypotension. Consistent return to semirecum- bent position should l be viewed quality indicator in patients receiving mechanica ventilation.\n\n6. A weaning protocol should be in place and ventilated mechanically patients should undergo a spontaneous breathing trial to evaluate the ability to discon- tinue mechanical ventilation when they satisfy the following criteria: a) arous- able; b) hemodynamically stable (with out vasop']","Reducing tidal volume to below predicted per kilogram of body weight every hour for 1-2 hours in ALI/ARDS patients can lower mortality rates by aiming for a <30 cm H₂O plateau pressure. Several past multiple-center randomized trials have shown that limiting tidal volume and pressure can decrease mortality rates in patients with ALI/ARDS. The largest trial of a volume- and pressure-limited strategy demonstrated a decrease in mortality rates in patients ventilated with tidal volumes of 6 mL/kg predicted body weight compared to 12 mL/kg, while aiming for a <30 cm H₂O plateau pressure.",error_correction,"[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}, {'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}]",True
脓毒症导致的ARDS患者应该怎么治疗以提高预后？,脓毒症导致的ARDS患者应该如何治疗以提高预后？,"['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动', '剂可以减少 ARDS 患者的住院时间， 显著减少机械通气天数， 但也导致心律失常和心动过速的患者数增加。\n推荐意见 32：对于脓毒症导致的 ARDS ，不推荐常规使用肺动脉置管 (强推荐，高证 据质量)。\n目前缺乏可证明使用肺动脉导管治疗改善患者预后的证据。两项多中心随机试验的合并 分析未能显示使用肺动脉导管对病死率或者 ICU 住院时间的任何受益。\n推荐意见 33 ：对于脓毒症导致的呼吸衰竭患者，在可以耐受脱机时， 推荐使用脱机方 案(强推荐，中等证据质量)。脓毒症患者计划脱机前，推荐进行自主呼吸试验(强推荐， 高证据质量)。\n2022ATS/ACCP 临床实践指南：机械通气脱机推荐对机械通气超过 24h 的成人患者使用 低水平压力支持进行初始自主呼吸试验。每日自主呼吸试验可减少患者机械通气时间和脱机 持续时。呼吸试验应与自主唤醒试验同时进行。 自主呼吸试验的成功可预示早期脱机的成功。 脱机方案包括自主呼吸试验、逐步减少压力支持和计算机辅助脱机。 合并分析表明， 与常规 治疗相比，采用方案化脱机治疗的患者脱机持续时间及 ICU 住院时间缩短， 而 ICU 病死率 或者重新机械通气比率之间�', '�异无统计学意义。\n7.8   镇静和镇痛\n推荐意见 34：对于需要机械通气的脓毒症患者， 推荐应用最小剂量的连续性或者间断 性镇静，以达到特定的镇静目标(BPS)。\n有研究表明， 限制机械通气的重症患者镇静剂的应用可缩短患者机械通气时间、 ICU 住 院时间及总住院时间， 并可促进患者的早期活动，由此可判断脓毒症患者也会从最小化镇静 中获益。 限制镇静剂的使用包括如下几种方法： 包含镇静评估的护理方案、使用间歇镇静而 不是持续镇静、使用阿片类药物而避免镇静剂的使用及使用短效药物如丙泊酚、右美托咪定 等，均证明可使需要机械通气的患者获益。\n7.9   血糖管理\n推荐意见35：对于 ICU 脓毒症患者， 推荐采用程序化血糖管理方案，推荐每 1-2h 监测 一次血糖，连续两次测定血糖＞10mmol/L 时启用胰岛素治疗， 目标血糖为≤10mmol/L (强 推荐，高证据质量)，血糖水平及胰岛素用量稳定后每 4h 监测一次(BPS)。建议对有动脉 置管的患者采集动脉血测定血糖(弱推荐，低证据质量)。\n多项 RCTs  结果表明，与传统血糖控制 ( 10.0-11.1mmol/L) 相比， 胰岛素强化治疗     (3.9-6.1mmol/L) 未显著降低 ICU ']",['，推荐使用限制性液体 治疗策略 (强推荐， 中等证据质量)。\n如有侵权请联系网站删除\nARDS 患者肺水肿的发病机制包括毛细血管通透性的增加、静水压力的增加及胶体渗透 压的降低。研究表明， 对 ARDS 的限制性液体治疗策略可减少患者的机械通气时间及 ICU 住 院时间， 且对肾衰竭发生率及病死率无显著影响。 限制性液体策略对降低脓毒症患者 ARDS 的发生率有益处， 在发生脓毒性休克的 12h 以内， 血管外肺水指数的下降意味着生存率的提 高。 小样本研究显示， 对重症患者采用限制性液体策略与采用液体正平衡策略相比， 病死率 更低，机械通气时间更短，住院时间更短。对 1000 例急性肺损伤的患者进行研究发现，与 开放液体治疗组相比较， 限制性液体治疗组患者 60d 病死率未见明显改善，而氧合改善，肺 损伤评分降低，机械通气时间缩短。\n推荐意见 31 ：对于脓毒症导致的 ARDS，如果无支气管痉挛，不推荐使用β-2 受体激 动剂(强推荐，中等证据质量)。\n几项 RCT s 研究评估了β-2 受体激动剂在 ARDS 患者中的使用， 其中两项试验由于无 效或者损伤而较早终止。合并分析表明， β-2 受体激动'],对于脓毒症导致的ARDS，推荐使用限制性液体治疗策略，该策略可以减少患者的机械通气时间及ICU住院时间，对肾衰竭发生率及病死率无显著影响。限制性液体策略也有益于降低脓毒症患者ARDS的发生率。对重症患者采用限制性液体策略相比液体正平衡策略，病死率更低，机械通气时间更短，住院时间更短。,error_correction,[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}],True
中国医士协会怎样通过《中国农毒症／农毒性休克急诊治疗指南 (2022)》来指导急诊与危重症医学工作者对农毒症和农毒性休克的治疗？,中国医师协会怎样通过《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》来指导急诊与危重症医学工作者对脓毒症和脓毒性休克的治疗？,"['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规']","['如有侵权请联系网站删除\n中国脓毒症/脓毒性休克急诊治疗指南(2022)\n脓毒症和脓毒性休克是急危重症医学面临的重要临床问题， 全球每年脓毒症患病人数超 过 1900 万，其中有 600 万患者死亡，病死率超过1/4，存活的患者中约有 300 万人存在认 知功能障碍。 早期识别与恰当处理可改善脓毒症患者的预后。 近年来， 国内外对脓毒症领域 的研究不断深入， 临床实践及证据不断增加， 2022 年美国重症医学会 (SCCM)与欧洲重症 医学会(ESICM 联合发布脓毒症3 .定义及诊断标准，新定义的浮现及临床证据的积累都会 对临床决策产生重要影响。为了更好地指导我国急诊与危重症医学工作者对脓毒症和脓毒性 休克的治疗， 中国医师协会急诊医师分会和中国研究型医院学会休克与脓毒症专业委员会组 织专家基于循证医学的方法制定了《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》(以下 简称为“本指南”)。\n1   检索策略 (略)\n2   推荐等级 (略)\n3   投票过程 (略)\n4   定义\n脓毒症是指因感染引起的宿主反应失调导致的危及生命的器官功能障碍。脓毒性休克定 义为脓毒症合并严重的循环、细胞和代谢紊乱，其死亡风险较', '单纯脓毒症更高。\n本指南虽然更新了脓毒症的定义， 但是在制定时选用的临床证据还是沿用了之前定义的 脓毒症、严重脓毒症、脓毒性休克。\n5   诊断标准\n对于感染或者疑似感染的患者， 当脓毒症相关序贯器官衰竭评分较基线( t)上升≥2 分可诊 断为脓毒症，见表6 。由于 SOFA 评分操作起来比较复杂，临床上也可以使用床旁快速 SOFA     (quick SOFA)标准识别重症患者， 见表7，如果符合 qSOFA 标准中的至少2项时，应进 一步评估患者是否存在脏器功能障碍。脓毒性休克为在脓毒症的基础上，浮现持续性低血压， 在充分容量复苏后仍需血管活性药来维持平均动脉压 (MAPP) ≥65mmHg  (1mmHg＝0.133 kPa) 以及血乳酸浓度＞2mmol/L 。\n脓毒症和脓毒性休克的临床诊断流程见图 1。\n如有侵权请联系网站删除\n6   诊断\n推荐意见1： 对于怀疑脓毒症或者脓毒性休克患者， 在不显著延迟启动抗菌药物治疗的前 提下，推荐常规进行微生物培养(至少包括两组血培养) (BPS)。\n在抗菌药物治疗开始之前先采样培养与改善预后有关。 如果能及时采样， 则先采集血样 进行培养； 如果不能即将获得标本， 尽快启动抗菌药物治疗。 患者的标本来�']",中国医师协会通过《中国脓毒症／脓毒性休克急诊治疗指南 (2022)》来指导急诊与危重症医学工作者对脓毒症和脓毒性休克的治疗，以提供早期识别与恰当处理，从而改善患者的预后。,error_correction,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
"How does hemodinamic status guid fluid ressucitation in patients with sepis, and what are its implictions for their managment?","How does hemodynamic status guide fluid resuscitation in patients with sepsis, and what are its implications for their management?","['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']","['操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '��包括血液、脑 脊液、尿液、伤口、呼吸道分泌物及其他体液，普通不包括有创操作的标本来源。如果临床 检查明确提示感染部位，则不需要对其他部位进行采样(除血样外)。对于留置静脉导管超 过 48h 且感染部位不明的患者， 建议至少进行需氧瓶和厌氧瓶两组血培养。 对于怀疑导管感 染的患者， 建议一组血标本经皮肤穿刺抽取，一组血标本由每一个血管通路装置分别抽取。\n7   治疗\n7.1   液体复苏\n推荐意见 2：脓毒性休克患者的液体复苏应及早开始(BPS)；对脓毒症所致的低灌注， 推荐在拟诊为脓毒性休克起 3h 内输注至少 30ml/kg 的晶体溶液进行初始复苏 (强推荐， 低 证据质量)；完成初始复苏后， 评估血流动力学状态以指导下一步的液体使用 (BPS)。\n早期开始液体复苏对于脓毒性休克至关重要。基于 Rivers 等提出的方案，较早的指南 已经推荐了标准化的定量复苏，称为早期目标导向性治疗(EGDT)。2022 年“拯救脓毒症运 动”对脓毒症集束化治疗进行更新，提出“1  小时集束化治疗”策略，进一步强调了应即将开 始复苏和治疗。 目前有干预试验将起始 3h 内赋予晶体溶液 30ml／kg 为早期复苏阶段的常 规', '操作， 也有观察性研究支持此项操作。 PROCESS 研究和 ARISE 研究中，患者平均液体输 注量约为 30ml／kg，对于需要更多液体量的患者， 应根据血流动力学评估结果以指导进一 步补液。 在重症监护期间持续的液体正平衡是有害的， 因此，在患者血流动力学指标持续改 善的前提下进行补液应谨慎，推荐进行补液试验评估液体反应性后再合理赋予液体 (BPS)。\n如有侵权请联系网站删除\n推荐意见 3：建议使用动态指标预测液体反应性(弱推荐，低证据质量)。\n采用被动抬腿试验、 容量负荷试验、 补液后每搏输出量的变化、收缩压变化、脉压变化 及机械通气后胸内压变化等动态检测指标预测液体反应性可以提高诊断精度。相关研究的回 顾性分析结果显示， 采用脉压变化预测脓毒症或者脓毒性休克患者的液体反应性具有高敏感度 及特异性。\n推荐意见4： 对于需使用血管活性药物的脓毒性休克患者，推荐以 MAPP 65mmHg 作 为初始复苏目标(强推荐，中等证据质量)；对于血乳酸水平升高的患者，建议以乳酸指导 复苏， 将乳酸恢复至正常水平 (弱推荐，低证据质量)。\nMAPP  是组织灌注的驱动力 ，在一定范围内反', '映组织灌注状态， 临床研究比较 65-85mmHg 范围内 MAPP 目标值与患者相关临床指标的改善情况发现，与 60mmHg 相比， 更高的 MAPP 目标值对患者 28d 及 90d 病死率、尿量、 肾功能、动脉乳酸水平等均无显著 改善，且可能增加患者心律失常风险，另有研究表明，在年龄大于 75 岁的患者中， 高 MAPP\n目标值与病死率的增加相关。 因此强烈推荐 MAPP 初始目标为 60mmHg ，但对于特殊患者， MAPP 目标值应根据患者的个体化情况而定，例如有高血压基础的脓毒性休克患者可能需要 维持较高的 MAPP。\n血乳酸水平与患者预后密切相关脓毒性休克患者早期动脉血乳酸 (LAC) 水平高提示， 预后不良，34h LAC 水平和乳酸清除率 (LCR)可有效评估临床治疗效果和预后。对 6477 例脓毒性休克患者以乳酸指导复苏的临床效果进行评估，与无乳酸监测复苏组相比，乳酸指 导复苏组患者病死率显著下降。对上述试验进行了Meta 分析结果显示， 与常规护理及采用 ScvO2 监测相比，采用早期乳酸清除策略可降低病死率。在一项评价参附注射液治疗脓毒性 休克的 RCT 研究中， LAC＞4.5mmol/L 的患者接受参附注射液治疗后， 其 7d生存率较对照 组显著提高。 一项�']","Hemodynamic status guides fluid resuscitation in patients with sepsis by evaluating parameters such as blood pressure, pulse pressure variation, and changes in cardiac output after fluid administration. This assessment helps determine the patient's fluid responsiveness and guides the appropriate administration of fluids. Continuous positive fluid balance during critical care is harmful, so fluid resuscitation should be cautious, especially when the patient's hemodynamic parameters are improving. It is recommended to assess fluid responsiveness through dynamic indicators before administering fluids.",error_correction,"[{'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}, {'filename': '(Word版)中国脓毒症／脓毒性休克急诊治疗指南(2022)培训资料.docx'}]",True
肾上腺功能不全如何在儿童感染性休克的诊断和治疗中发挥作用？,肾上腺功能不全如何在儿童感染性休克的诊断和治疗中发挥作用？,"['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']","['-. normal men tal status, decreased lactate and increased base deficit., and superior vena icava or mixed ve nous oxvgen saturation >70%, When employ. ing measurements to assist in identifving ac : output in ceptable cardiac children with systemic arterial hypoxemia such as cvanotic congenital heart disease or severe pulmonar disease, arterial-venous oxvgen content differ ence is a better marker than mixed venous hemoglobin saturation with oxvgen. Optimiz- ing preload optimizes cardiac index., As noted previously, blood pressure by itself is s not a reliable e end point for resuscitation. If a pul- therapeutic catheter is used monary artery cardiac index >3.3 and <6.0 end points are L.min- .m with normal perfusion pressure (mean arterial pressure/central Ivenous pres sure) for age 5. Approach to Pediatric Septic Shock. Fig ure 1 shows a flow diagram summarizing an approach to pediatric septic shock (121) 6. Steroids. Hydrocortisone therapy should be reserved for use in children with catechol amine resistance and suspected or proven ad renal insufficiency. Patients s at risk include children with severe septic shock and purpura (122, 123), children who have previously re- ceived steroid therapies for chronic illness and children with pituitary or adrenal abnor malities. There are no strict defnitions, but adrenal of insufficiency in the case cate- cholamine-resistant septic shock is assumed at a random total cortisol concentration <la μg/dL (496 nmol/L). There is no clear consen sus for the role of or best steroids dose of steroids in children with septic shock. A pos 30- or 60-min ACTH stimulation test increase in cortisol of ≤9 ug/dL (248 nmol/L) also makes that diagnosis. Two randomized controlled trial: used ""shock dose"" hydrocortisone (25 time: higher than the stress dose) in children, both ir dengue fever. The results were conflicting (124 125). Dose recommendations vary from 1-2 mg/kg for stress coverage (based on clinical di agnosis of adrenal insufficiency) to 50 mg/kg fo empirical therapy of shock followed by the same dose as a 24-hr infusion 7. Protein C and Activated Protein C. Pro tein C concentrations in children reach adul\n\nCrit Care Med 2004 Vol. 32, No. 3\n\ntation either as protein C concentrate or as rhAPC is even greater in young children thar in adults, There has been one dose finding placebo-controlled study performed using pro tein C concentrate. This study was not pow ered to show an effect on mortality rate bu did show a positive effect on sepsis-induced coagulation disturbances (126. 127). No ran domized studies using rhAPC have been per formed 8 Gramulocute Macrophage Colonu Stim ulating Factor, Growth factors or white blood cell transfusions are oiven to natients witl secondary to chemother neutronenic sensis any or white blood cell primary immune defi ciency A randomized controlled trial showed imnroved 1 outcomes in neonates with sepsis and an absolute neutrophil count <1500/ul (1.5 5 x 109L) treated with a 7-day course of granulocvte macronhage colony stimulatins factor (128 129) 9 DVT Pronhulaxis. Most DVTs in young children are associated with central venous catheters Femoral venous catheters are com monly used in children, and central venous catheter-associated DVT occurs in approximatel 25% of children with a femoral central venous catheter. There are no data on use of heparir prophylaxis to prevent DVT in children 10. Stress Ulcer Prophulaxis, No studies have been performed in children analyzing the effect of stress ulcer prophylaxis. Studies have shown that the rate of clinically importan gastrointestinal bleeding in children occurs a rates similar to adults (130, 131). As in adults coagulopathy and mechanical ventilation are risk factors for clinically important gastroin testinal bleeding. Stress ulcer r prophylaxis strategy is commonly used in mechanicall ventilated children, usually with H, blockers Its eftect is not known 11. Renal Replacement Therapy. Continu ous venovenous hemofiltration may be clini cally useful in children with anuria/severe ol iguria and fluid overload. but no large RCT have been performed 12. Glycemic Control. In general, infants at risk for developing g hypoglycemia when thev depend on intravenous']",nan,error_correction,[{'filename': '2004+SSC+严重脓毒症与脓毒性休克治疗国际指南.pdf'}],True
"What is the signaficance of ""Keine B2-Agonisten"" in this contex regarding noninvazive ventilation recommedations?","What is the significance of ""Keine B2-Agonisten"" in this context regarding noninvasive ventilation recommendations?","['                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ', '                                                                                                                                  | Starke Empfehlunc                                   |\n| 11 | nan    | nan                         | Keine B2-Agonisten, aulser bei Bronchospasmus                                                                                                                                                                                                                                                | Evidenz moderat                                     |\n| 12 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Starke EmpfehlungEvidenz moderat                    |\n| 13 | nan    | nan                         | Kein Routineeinsatz des Pulmonaliskatheterlumina                                                                                         ']","['                                                                                                                     | Starke EmpfehlungEvidenz moderat                    |\n|  8 | nan    | nan                         | Keine spezifische Empfehlung zu NIV (nichtinvasive Beatmung                                                                                                                                                                                                                                  | -                                                   |\n|  9 | nan    | nan                         | nan                                                                                                                                                                                                                                                                                          | Evidenz moderat                                     |\n| 10 | nan    | nan                         | Restriktive Volumengabe, wenn keine Hypoperfusion vorliegt                                                                                                 ']",nan,error_correction,[{'filename': 'Briegel-2017-[International guidelines from th.pdf'}],True
